Option Care Health (OPCH) 10-Q 6 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 04, 2019
Document Entity Information [Abstract]
Entity Registrant Name	Option Care Health, Inc.
Entity Central Index Key	0001014739
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		705,849,364
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Current Reporting Status	Yes

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
CURRENT ASSETS:
Cash and cash equivalents	$ 52,789	$ 36,391
Accounts receivable, net	336,303	310,169
Inventories	109,235	83,340
Prepaid expenses and other current assets	46,919	37,525
Total current assets	545,246	467,425
NONCURRENT ASSETS:
Property and equipment, net	131,982	93,142
Operating lease right-of-use asset	68,042	0
Intangible assets, net	395,078	219,713
Goodwill	1,419,373	632,469
Other noncurrent assets	22,204	15,462
Total noncurrent assets	2,036,679	960,786
TOTAL ASSETS	2,581,925	1,428,211
CURRENT LIABILITIES
Accounts payable	213,149	187,886
Accrued compensation and employee benefits	48,406	24,895
Accrued expenses and other current liabilities	29,635	23,066
Current portion of operating lease liability	21,540	0
Long-term debt - current portion	6,938	4,150
Total current liabilities	319,668	239,997
NONCURRENT LIABILITIES:
Long-term debt, net of discount, deferred financing costs and current portion	1,259,460	535,225
Operating lease liability, net of current portion	62,424	0
Deferred income taxes	1,498	33,481
Other noncurrent liabilities	17,193	16,683
Total noncurrent liabilities	1,340,575	585,389
Total liabilities	1,660,243	825,386
Commitments and Contingencies
STOCKHOLDERS’ EQUITY:
Preferred stock; $0.001 par value; 50,000,000 shares authorized, no shares outstanding as of September 30, 2019. No preferred stock authorized or outstanding as of December 31, 2018.	0	0
Common stock; $0.0001 par value: 1,000,000,000 shares authorized, 706,943,750 shares issued and 705,207,530 shares outstanding as of September 30, 2019; 570,454,995 shares issued and outstanding as of December 31, 2018.	71	57
Treasury stock; 1,736,220 shares outstanding, at cost, as of September 30, 2019; no shares outstanding as of December 31, 2018	(2,399)	0
Paid-in capital	1,008,037	619,578
Management notes receivable	0	(1,619)
Accumulated deficit	(76,144)	(16,035)
Accumulated other comprehensive (loss) income	(7,883)	844
Total stockholders’ equity	921,682	602,825
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 2,581,925	$ 1,428,211

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	50,000,000	0
Preferred stock, shares, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares, issued (in shares)	706,943,750	570,454,995
Common stock, shares, outstanding (in shares)	705,207,530	570,454,995
Treasury stock, at cost (in shares)	1,736,220	0

UNAUDITED CONDENSED CONSOLIDATE

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
NET REVENUE	$ 615,880	$ 493,928	$ 1,589,638	$ 1,434,061
COST OF REVENUE	478,107	385,683	1,252,281	1,122,846
GROSS PROFIT	137,773	108,245	337,357	311,215
OPERATING COSTS AND EXPENSES:
Selling, general and administrative expenses	133,475	85,929	315,815	258,314
Depreciation and amortization expense	16,023	9,557	36,142	28,180
Total operating expenses	149,498	95,486	351,957	286,494
OPERATING (LOSS) INCOME	(11,725)	12,759	(14,600)	24,721
OTHER INCOME (EXPENSE):
Interest expense, net	(21,509)	(11,025)	(44,117)	(34,313)
Equity in earnings of joint ventures	826	301	2,018	656
Other, net	(6,810)	139	(6,679)	(2,170)
Total other expense	(27,493)	(10,585)	(48,778)	(35,827)
(LOSS) INCOME BEFORE INCOME TAXES	(39,218)	2,174	(63,378)	(11,106)
INCOME TAX EXPENSE (BENEFIT)	3,576	383	(3,269)	(1,737)
NET (LOSS) INCOME	(42,794)	1,791	(60,109)	(9,369)
OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX:
Change in unrealized (losses) gains on cash flow hedges, net of income taxes of $32, ($34), $259 and ($530), respectively	(8,249)	187	(8,727)	1,635
OTHER COMPREHENSIVE (LOSS) INCOME	(8,249)	187	(8,727)	1,635
NET COMPREHENSIVE (LOSS) INCOME	$ (51,043)	$ 1,978	$ (68,836)	$ (7,734)
(LOSS) EARNINGS PER COMMON SHARE
Net (loss) income per share, basic and diluted (in dollars per share)	$ (0.07)	$ 0	$ (0.10)	$ (0.02)
Weighted average common shares outstanding, basic and diluted (in shares)	651,576	570,455	597,792	570,455

UNAUDITED CONDENSED CONSOLIDA_2

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Income taxes on unrealized gains (losses) on cash flow hedges	$ 32	$ (34)	$ 259	$ (530)

UNAUDITED CONDENSED CONSOLIDA_3

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (60,109)	$ (9,369)
Adjustments to reconcile net loss to net cash provided by operations:
Depreciation and amortization expense	38,997	30,447
Non-cash operating lease costs	15,246	0
Deferred income taxes - net	(5,252)	(2,091)
Loss on extinguishment of debt	5,469	72
Amortization of deferred financing costs	3,057	2,286
Equity in earnings of joint ventures	(2,018)	(656)
Stock-based incentive compensation expense	3,898	1,671
Other adjustments	1,046	640
Changes in operating assets and liabilities:
Accounts receivable, net	71,029	(32,483)
Inventories	(6,212)	4,010
Prepaid expenses and other current assets	1,447	(593)
Accounts payable	(36,157)	8,683
Accrued compensation and employee benefits	5,312	615
Accrued expenses and other current liabilities	(3,846)	9,309
Operating lease liabilities	(11,922)	0
Other noncurrent assets and liabilities	(3,415)	(343)
Net cash provided by operating activities	16,570	12,198
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment	(13,150)	(20,716)
Other investing cash flows	636	0
Business acquisitions, net of cash acquired	(700,170)	(9,917)
Net cash used in investing activities	(712,684)	(30,633)
CASH FLOWS FROM FINANCING ACTIVITIES:
Redemptions to related parties	(2,000)	0
Sale of management notes receivable	1,310	0
Exercise of stock options, vesting of restricted stock, and related tax withholdings	(2,497)	0
Proceeds from debt	981,050	1,000
Repayments of debt principal	(2,075)	(4,112)
Retirement of debt obligations	(226,738)	0
Deferred financing costs	(36,538)	0
Net cash provided by (used in) financing activities	712,512	(3,112)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	16,398	(21,547)
Cash and cash equivalents - beginning of the period	36,391	53,116
CASH AND CASH EQUIVALENTS - END OF PERIOD	52,789	31,569
Supplemental disclosure of cash flow information:
Cash paid for interest	35,531	32,110
Cash paid for income taxes	1,617	1,246
Cash paid for operating leases	$ 15,248

UNAUDITED CONDENSED CONSOLIDA_4

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Preferred Stock	Common Stock	Treasury Stock	Paid-in Capital	Management Notes Receivable	Accumulated Deficit	Accumulated Other Comprehensive (Loss) Income
Equity, beginning balance at Dec. 31, 2017	$ 606,105	$ 0	$ 57	$ 0	$ 617,014	$ (1,116)	$ (9,920)	$ 70
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' contribution	0				425	(425)
Interest on management notes receivable	(17)					(17)
Stock-based incentive compensation	438				438
Net income (loss)	(6,851)						(6,851)
Other comprehensive income	1,030							1,030
Equity, ending balance at Mar. 31, 2018	600,705	0	57	0	617,877	(1,558)	(16,771)	1,100
Equity, beginning balance at Dec. 31, 2017	606,105	0	57	0	617,014	(1,116)	(9,920)	70
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(9,369)
Other comprehensive income	1,635
Equity, ending balance at Sep. 30, 2018	599,985	0	57	0	619,110	(1,598)	(19,289)	1,705
Equity, beginning balance at Mar. 31, 2018	600,705	0	57	0	617,877	(1,558)	(16,771)	1,100
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Interest on management notes receivable	(20)					(20)
Stock-based incentive compensation	668				668
Net income (loss)	(4,309)						(4,309)
Other comprehensive income	418							418
Equity, ending balance at Jun. 30, 2018	597,462	0	57	0	618,545	(1,578)	(21,080)	1,518
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Interest on management notes receivable	(20)					(20)
Stock-based incentive compensation	565				565
Net income (loss)	1,791						1,791
Other comprehensive income	187							187
Equity, ending balance at Sep. 30, 2018	599,985	0	57	0	619,110	(1,598)	(19,289)	1,705
Equity, beginning balance at Dec. 31, 2018	602,825	0	57	0	619,578	(1,619)	(16,035)	844
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Interest on management notes receivable	(21)					(21)
Stockholders' redemption	(2,000)				(2,000)
Stock-based incentive compensation	584				584
Net income (loss)	(3,712)						(3,712)
Other comprehensive income	(505)							(505)
Equity, ending balance at Mar. 31, 2019	597,171	0	57	0	618,162	(1,640)	(19,747)	339
Equity, beginning balance at Dec. 31, 2018	602,825	0	57	0	619,578	(1,619)	(16,035)	844
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(60,109)
Other comprehensive income	(8,727)
Equity, ending balance at Sep. 30, 2019	921,682	0	71	(2,399)	1,008,037	0	(76,144)	(7,883)
Equity, beginning balance at Mar. 31, 2019	597,171	0	57	0	618,162	(1,640)	(19,747)	339
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Interest on management notes receivable	(18)					(18)
Stockholders' redemption	0				(371)
Stock-based incentive compensation	569				1
Net income (loss)	(13,603)						(13,603)
Other comprehensive income	27							27
Equity, ending balance at Jun. 30, 2019	584,146	0	57	0	618,360	(1,287)	(33,350)	366
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Interest on management notes receivable	(23)					(23)
Repayment of management notes receivable	1,310					1,310
Purchase of BioScrip, Inc.	387,044		14		387,030
Stock-based incentive compensation	2,745				2,745
Exercise of stock options, vesting of restricted stock, and related tax withholdings	(2,497)			(2,399)	(98)
Net income (loss)	(42,794)						(42,794)
Other comprehensive income	(8,249)							(8,249)
Equity, ending balance at Sep. 30, 2019	$ 921,682	$ 0	$ 71	$ (2,399)	$ 1,008,037	$ 0	$ (76,144)	$ (7,883)

NATURE OF OPERATIONS AND PRESEN

NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Presentation of Financial Statements	NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS Corporate Organization and Business — HC Group Holdings II, Inc. (“HC II”) was incorporated under the laws of the State of Delaware on January 7, 2015, with its sole shareholder being HC Group Holdings I, LLC. (“HC I”). On April 7, 2015, HC I and HC II collectively acquired Walgreens Infusion Services, Inc. and its subsidiaries from Walgreen Co., and the business was rebranded as Option Care (“Option Care”). On March 14, 2019, HC I and HC II entered into a definitive agreement (the “Merger Agreement”) to merge with and into a wholly-owned subsidiary of BioScrip, Inc. (“BioScrip”), a national provider of infusion and home care management solutions, along with certain other subsidiaries of BioScrip and HC II. The merger contemplated by the Merger Agreement (the “Merger”) was completed on August 6, 2019 (the “Merger Date”). The Merger was accounted for as a reverse merger under the acquisition method of accounting for business combinations with Option Care being considered the accounting acquirer and BioScrip being considered the legal acquirer. Under the terms of the Merger Agreement, shares of HC II common stock issued and outstanding immediately prior to the Merger Date were converted into 542,261,567 shares of BioScrip common stock, par value $0.0001 (the “BioScrip common stock”). BioScrip also issued an additional 28,193,428 shares to HC I in respect of certain outstanding unvested contingent restricted stock units of BioScrip, which are held in escrow to prevent dilution related to potential additional vesting on certain share-based instruments. See Note 16, Stockholders’ Equity , for additional discussion of these shares held in escrow. In conjunction with the Merger, holders of BioScrip preferred shares and certain warrants received 3,458,412 additional shares of BioScrip common stock and preferred shares were repurchased for $125.8 million of cash. In addition, all legacy BioScrip debt was settled for $575.0 million . As a result of the Merger, BioScrip’s stockholders hold approximately 19.1% of the combined company, and HC I holds approximately 80.9% of the combined company. Following the close of the transaction, BioScrip was rebranded as Option Care Health, Inc. (“Option Care Health”, or the “Company”). The combined company’s stock was listed on the Nasdaq Capital Market as of September 30, 2019 . See Note 3, Business Acquisitions , for further discussion on the Merger. Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of 132 locations. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. The Company operates in one segment, infusion services. Basis of Presentation — The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2018 audited consolidated financial statements, including the notes thereto, as presented in the definitive merger proxy with the Securities and Exchange Commission filed on June 26, 2019. Principles of Consolidation — The Company’s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. The BioScrip results have been included in the consolidated financial results since the Merger Date. All intercompany transactions and balances are eliminated in consolidation.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Leases — The Company has lease agreements for facilities, warehouses, office space and property and equipment. Effective as of January 1, 2019, at the inception of a contract, the Company determines if the contract is a lease or contains an embedded lease arrangement. Operating leases are included in the operating lease right-of-use asset (“ROU asset”) and operating lease liabilities in the condensed consolidated financial statements. ROU assets, which represent the Company’s right to use the leased assets, and operating lease liabilities, which represent the present value of unpaid lease payments, are both recognized by the Company at the lease commencement date. The Company utilizes its estimated incremental borrowing rate at the lease commencement date to determine the present value of unpaid lease obligations. The rates were estimated primarily using a methodology dependent on the Company’s financial condition, creditworthiness, and availability of certain observable data. In particular, the Company considered its actual cost of borrowing for collateralized loans and its credit rating, along with the corporate bond yield curve in estimating its incremental borrowing rates. ROU assets are recorded as the amount of operating lease liability, adjusted for prepayments, accrued lease payments, initial direct costs, lease incentives, and impairment of the ROU asset. Tenant improvement allowances used to fund leasehold improvements are recognized when earned and reduce the related ROU asset. Tenant improvement allowances are amortized through the ROU asset as a reduction of expense over the term of the lease. Leases may contain rent escalations, however the Company recognizes the lease expense on a straight-line basis over the expected lease term. The Company reviews the terms of any lease renewal options to determine if it is reasonably certain that the renewal options will be exercised. The Company has determined that the expected lease term is typically the minimum non-cancelable period of the lease. The Company has lease agreements that contain both lease and non-lease components, which the Company has elected to account for as a single lease component for all asset classes. Leases with an initial term of 12 months or less are not recorded on the condensed consolidated balance sheet and are expensed on a straight-line basis over the term of the lease. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. Stock Based Incentive Compensation — The Company accounts for stock-based incentive compensation expense in accordance with Accounting Standards Codification (“ASC”) Topic 718, Compensation-Stock Compensation (“ASC 718”). Stock-based incentive compensation expense is based on the grant date fair value. The Company estimates the fair value of stock option awards using a Black-Scholes option pricing model and the fair value of restricted stock unit awards using the closing price of the Company’s common stock on the grant date. For awards with a service-based vesting condition, the Company recognizes expense on a straight-line basis over the service period of the award. For awards with performance-based vesting conditions, the Company will recognize expense when it is probable that the performance-based conditions will be met. When the Company determines that it is probable that the performance-based conditions will be met, a cumulative catch-up of expense will be recorded as if the award had been vesting on a straight-line basis from the award date. The award will continue to be expensed on a straight-line basis through the remainder of the vesting period and will be updated if the Company determines that there has been a change in the probability of achieving the performance-based conditions. The Company records the impact of forfeited awards in the period in which the forfeiture occurs. Prior to the Merger, HCI issued incentive units to certain employees of Option Care, who remained employees of the Company following the Merger. In accordance with ASC 718, the Company recognizes compensation expense on a straight-line basis over the shorter of the vesting period of the award or the employee’s expected eligibility date. HC I also issued equity incentive units to certain members of the Option Care Board of Directors, who remained members of the Board of Directors following the Merger. In accordance with ASC Topic 505, Equity Based Payment to Non-Employees , expense was recognized at grant date. See Note 15, Stock-Based Incentive Compensation , for a further discussion of equity incentive plans. Concentrations of Business Risk — The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 15% and 13% for the three and nine months ended September 30, 2019 , respectively. Revenue related to the Company’s largest payer was approximately 16% and 14% for the three and nine months ended September 30, 2018 , respectively. For the three and nine months ended September 30, 2019 , approximately 13% and 12% , respectively, of the Company’s revenue was reimbursable through Medicare and Medicaid. For the three and nine months ended September 30, 2018 , approximately 11% and 11% , respectively, of the Company’s revenue was reimbursable through Medicare and Medicaid. As of September 30, 2019 and December 31, 2018 , respectively, approximately 14% and 13% , respectively, of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term. Concentration of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. For the three and nine months ended September 30, 2019 , approximately 69% and 72% , respectively, of the Company’s pharmaceutical and medical supply purchases were from three vendors. For the three and nine months ended September 30, 2018 , approximately 75% and 76% , respectively, of the Company’s pharmaceutical and medical supply purchases were from three vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company’s financial condition or operating results. Recently-Adopted Accounting Pronouncements — In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, Leases , intended to improve financial reporting about leasing transactions. The new guidance requires entities that lease assets to recognize on their balance sheets the ROU assets and lease liabilities for the rights and obligations created by those leases and to disclose key information about leasing arrangements. ASU 2016-02 is effective for interim and annual periods beginning after December 15, 2018 for public entities and certain not-for-profits. The Company adopted the standard as of January 1, 2019. ASU 2016-02 allows for an optional transition method, which was elected by the Company, and permits the application of the standard as of the effective date without requiring the standard to be applied to the comparative periods presented in the unaudited condensed consolidated financial statements. The Company elected the transition package of three practical expedients allowed by ASU 2016-02, which allows the Company not to reassess prior conclusions about lease identification, lease classification and initial, direct costs. The Company did not elect the practical expedient to use hindsight and, accordingly, the initial lease term did not differ under the new standard versus prior accounting practice. The Company also made a policy election not to apply this standard to any leases with a term of 12 months or less. Adoption of ASU 2016-02 resulted in the Company recording an operating lease liability of $67.0 million and a corresponding ROU asset of $59.9 million in the unaudited condensed consolidated balance sheet as of January 1, 2019. See Note 7, Leases , for further discussion on leases. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers . The ASU requires that an entity recognizes revenue to depict the transfer of promised goods or services to a customer in an amount that reflects the consideration to which the Company expects to be entitled in exchange for these goods or services. ASU 2014-09 is effective for interim and annual reporting periods beginning after December 15, 2017 for public entities and certain not-for-profits. The Company adopted the standard as of January 1, 2018. ASU 2014-09 allows for a modified retrospective approach upon adoption, which was elected by the Company, and permits application of the standard only to contracts that are not completed at the adoption date with no adjustment to the comparative periods presented in the unaudited condensed consolidated financial statements. The Company also elected the practical expedient for the portfolio approach, allowing contracts with similar characteristics and impacts to the financial statements to be evaluated together. ASU 2014-09 requires the Company to recognize revenue as the amount of cash that is ultimately expected to be collected, which resulted in the Company treating its previously-reported provision for doubeful accounts as an implicit price concession and a reduction to revenue. Other than the treatment of bad debt expense, the adoption of this standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements. See Note 4, Revenue , for further discussion on revenue. In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting . ASU 2019-09 modifies when a change to the terms or conditions of share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the fair value, vesting condition, or the classification of the award is not the same immediately before and after a change to the terms and conditions of the award. The effective date for ASU 2017-09 is for annual or interim periods beginning after December 15, 2017. The Company adopted the standard as of January 1, 2018. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements. Recent Accounting Pronouncements — In June 2016, the FASB issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which requires measurement and recognition of expected credit losses for financial assets held. The Amendments in ASU 2016-13 eliminate the probable threshold for initial recognition of a credit loss in current GAAP and reflect an entity’s current estimate of all expected credit losses. ASU 2016-13 is effective for interim and annual reporting periods beginning after December 15, 2019, and is to be applied using a modified retrospective transition method. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. Immaterial Error Correction — During the three months ended September 30, 2019 , the Company identified prior period misstatements in the recording of other noncurrent liabilities that resulted in an overstatement of goodwill and other noncurrent liabilities in the Company’s consolidated balance sheets. The Company assessed the materiality of these misstatements both quantitatively and qualitatively and determined the correction of these errors to be immaterial to the prior consolidated financial statements taken as a whole. As a result, the Company has corrected the misstatements by decreasing goodwill and other noncurrent liabilities by $6.5 million in the accompanying condensed consolidated financial statements. The misstatements had no impact on net (loss) income or net cash flows from operating, investing, or financing activities in any of the periods presented.

BUSINESS ACQUISITIONS

BUSINESS ACQUISITIONS	9 Months Ended
	Sep. 30, 2019
Business Combinations [Abstract]
Business Acquisitions	BUSINESS ACQUISITIONS Merger with BioScrip, Inc. Overview and Total Consideration Exchanged — As discussed in Note 1, Nature of Operations and Presentation of Financial Statements, Option Care merged with BioScrip on August 6, 2019. BioScrip was a national provider of infusion and home care management solutions, that partnered with physicians, hospital systems, payers, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services. The Merger of Option Care and BioScrip into Option Care Health creates an expanded national platform and the opportunity to drive economies of scale through procurement savings, facility rationalization and other operating cost savings. The fair value of purchase consideration transferred on the closing date includes the value of the number of shares of the combined company owned by BioScrip shareholders at closing of the Merger, the value of common shares issued to certain warrant and preferred shareholders in conjunction with the Merger, the fair value of stock-based instruments that were vested or earned as of the Merger, and cash payments made in conjunction with the Merger. The fair value per share of BioScrip’s common stock was $2.67 per share. This is the closing price of the BioScrip common stock on August 6, 2019. Under the acquisition method of accounting, the calculation of total consideration exchanged is as follows (in thousands): Amount Number of BioScrip common shares outstanding at time of the Merger 129,181 Common shares issued to warrant and preferred stockholders at time of the Merger 3,458 Total shares of BioScrip common stock outstanding at time of the Merger 132,639 BioScrip share price as of August 6, 2019 $ 2.67 Fair value of common shares $ 354,146 Fair value of share-based instruments $ 32,898 Cash paid in conjunction with the Merger included in purchase consideration $ 714,957 Fair value of total consideration transferred $ 1,102,001 Less: cash acquired $ 14,787 Fair value of total consideration acquired, net of cash acquired $ 1,087,214 Cash paid in conjunction with the Merger includes payments made for settlement of $575.0 million in legacy BioScrip debt, $125.8 million in existing BioScrip preferred shares, and $14.1 million in legacy BioScrip success-based fees owed to third-party advisors. HC II financed these payments primarily through cash on hand and debt financing, which is discussed in Note 11, Indebtedness . Allocation of Consideration —The Company's allocation of consideration exchanged to the net tangible and intangible assets acquired and liabilities assumed in the Merger is based on estimated fair values as of the Merger Date. The fair values were determined based upon a preliminary valuation and the estimates and assumptions used in such valuation are pending completion and subject to change, which could be significant, within the measurement period, up to one year from the August 6, 2019 acquisition date. The following is a preliminary estimate of the allocation of the consideration transferred to acquired identifiable assets and assumed liabilities, net of cash acquired, in the Merger as of August 6, 2019 (in thousands): Amount Accounts receivable, net (1) $ 97,163 Inventories (2) 19,683 Property and equipment, net (3) 49,697 Intangible assets, net (4) 193,712 Deferred tax assets, net of deferred tax liabilities (5) 26,731 Operating lease right-of-use asset (6) 22,378 Operating lease liability (6) (28,897 ) Accounts payable (7) (61,420 ) Other assumed liabilities, net of other acquired assets (7) (18,737 ) Total acquired identifiable assets and liabilities 300,310 Goodwill (8) 786,904 Total consideration transferred $ 1,087,214 (1) Management has valued accounts receivables based on the estimated future collectability of the receivables portfolio, which approximates fair value. (2) Inventories are stated at fair value as of the Merger Date. (3) The fair value of the property and equipment was determined based upon the best and highest use of the property with final values determined based upon an analysis of the cost, sales comparison, and income capitalization approaches for each property appraised. (4) The preliminary allocation of consideration exchanged to intangible assets acquired is as follows (in thousands): Fair Value Weighted Average Estimated Life (in years) Trademarks/Names $ 12,681 2 Patient referral sources 180,652 20 Licenses 379 1.5 Total intangible assets, net $ 193,712 18.8 The Company preliminarily valued these intangibles utilizing the multi-period excess earnings method, a form of the income approach. (5) Net deferred tax assets represented the expected future tax consequences of temporary differences between the fair values of the assets acquired and liabilities assumed and their tax bases. See Note 5, Income Taxes , for additional discussion of the Company’s combined income tax position subsequent to the Merger. (6) The fair value of the operating lease liability and corresponding right-of-use asset (current and long-term) was based on current market rates available to the Company. (7) Accounts payable as well as certain other current and non-current assets and liabilities are stated at fair value as of the Merger Date. (8) The Merger preliminarily resulted in $786.9 million of goodwill, which is attributable to cost synergies resulting from procurement and operational efficiencies and elimination of duplicative administrative costs. The goodwill created in the Merger is not expected to be deductible for tax purposes. Pro Forma — Assuming BioScrip had been acquired as of January 1, 2018, and the results of BioScrip had been included in operations beginning on January 1, 2018, the following tables provide estimated unaudited pro forma results of operations for the three and nine months ended September 30, 2019 and 2018 (in thousands). The estimated pro forma net income adjusts for the effect of fair value adjustments related to the Merger, transaction costs and other non-recurring costs directly attributable to the Merger and the impact of the additional debt to finance the Merger. Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Net revenue $ 690,350 $ 674,890 $ 2,034,582 $ 1,959,395 Net loss (18,686 ) (7,919 ) (54,181 ) (59,670 ) Estimated unaudited pro forma information is not necessarily indicative of the results that actually would have occurred had the Merger been completed on the date indicated or the future operating results. For the periods subsequent to the Merger Date that are included in the results of operations for the three and nine months ended September 30, 2019 , BioScrip had net revenue of $119.1 million and a net loss of $19.4 million . Transaction Expenses — Acquisition-related costs were expensed as incurred, with the exception of success-based fees that are included in consideration transferred. The Company recorded transaction costs that are expensed in selling, general and administrative expenses during the three and nine months ended September 30, 2019 of approximately $6.5 million and $19.3 million , respectively. Transaction expenses consisted of professional fees for advisory, consulting and underwriting services as well as other incremental costs directly related to the acquisition. Baptist Health Asset Acquisition — In August 2018, pursuant to the Purchase and Sale Agreement dated August 8, 2018, Option Care completed the acquisition of certain assets of Baptist Health in Little Rock, Arkansas for a purchase price of $1.0 million . Home I.V. Specialists, Inc. Acquisition — In September 2018, pursuant to the Stock Purchase Agreement dated September 18, 2018, Option Care completed the acquisition of 100% of the outstanding shares of Home I.V. Specialists, Inc. for a purchase price of $11.6 million , net of cash acquired.

REVENUE

REVENUE	9 Months Ended
	Sep. 30, 2019
Revenue from Contract with Customer [Abstract]
Revenue	REVENUE On January 1, 2018, the Company adopted ASC 606, Revenue from Contracts with Customers using the modified retrospective approach applied to those contracts that were not completed as of that date. The Company did not record a cumulative catch-up adjustment, as the timing and measurement of revenue for the Company’s customers is similar to its prior revenue recognition model. ASC 606 requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to in exchange for those goods or services. ASC 606 requires application of a five-step model to determine when to recognize revenue and at what amount. The revenue standard applies to all contracts with customers and revenues are to be recognized when control of the promised goods or services is transferred to the Company’s patients in an amount that reflects consideration expected to be received in exchange for those goods or services. Adoption of the standard impacted the Company’s results as follows (in thousands): Prior to ASC 606 Adoption Adjustments for ASC 606 Subsequent to ASC 606 Adoption As of September 30, 2019 Condensed Consolidated Balance Sheets Accounts receivable, net $ 336,303 $ — $ 336,303 Nine Months Ended September 30, 2019 Condensed Consolidated Statement of Comprehensive Income (Loss) Net revenue $ 1,644,903 $ (55,265 ) $ 1,589,638 Provision for doubtful accounts (55,265 ) 55,265 — Operating loss (14,600 ) — (14,600 ) Condensed Consolidated Statements of Cash Flows Changes in operating cash flows: Accounts receivable, net 71,029 — 71,029 As of December 31, 2018 Condensed Consolidated Balance Sheets Accounts receivable, net $ 310,169 $ — $ 310,169 Nine Months Ended September 30, 2018 Condensed Consolidated Statement of Comprehensive Income (Loss) Net revenue $ 1,479,058 $ (44,997 ) $ 1,434,061 Provision for doubtful accounts (44,997 ) 44,997 — Operating Income 24,721 — 24,721 Condensed Consolidated Statements of Cash Flows Changes in operating cash flows: Accounts receivable, net (32,483 ) — (32,483 ) Net revenue is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services. Revenues are from government payers, commercial payers, and patients for goods and services provided and are based on a gross price based on payer contracts, fee schedules, or other arrangements less any implicit price concessions. Due to the nature of the health care industry and the reimbursement environment in which the Company operates, certain estimates are required to record revenue and accounts receivable at their net realizable values at the time goods or services are provided. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. The Company assesses the expected consideration to be received at the time of patient acceptance based on the verification of the patient’s insurance coverage, historical information with the patient, similar patients, or the payer. Performance obligations are determined based on the nature of the services provided by the Company. The majority of the Company’s performance obligations are to provide infusion services to deliver medicine, nutrients, or fluids directly into the body. The Company provides a variety of therapies to patients. For infusion-related therapies, the Company frequently provides multiple deliverables of pharmaceutical drugs and related nursing services. After applying the criteria from ASC 606, the Company concluded that multiple performance obligations exist in its contracts with its customers. Revenue is allocated to each performance obligation based on relative standalone price, determined based on reimbursement rates established in the third-party payer contracts. Pharmaceutical drug revenue is recognized at the time the pharmaceutical drug is delivered to the patient, and nursing revenue is recognized on the date of service. The Company's outstanding performance obligations relate to contracts with a duration of less than one year. Therefore, the Company has elected to apply the practical expedient provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. Any unsatisfied or partially unsatisfied performance obligations at the end of a reporting period are generally completed prior to the patient being discharged. The following table sets forth the net revenue earned by category of payer for the three and nine months ended September 30, 2019 and 2018 (in thousands): Three Months Ended Nine Months Ended 2019 2018 2019 2018 Commercial payers $ 525,927 $ 428,873 $ 1,373,481 $ 1,256,109 Government payers 80,280 56,511 194,875 160,939 Patients 9,673 8,544 21,282 17,013 Net revenue $ 615,880 $ 493,928 $ 1,589,638 $ 1,434,061

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES During the three and nine months ended September 30, 2019 , the Company recorded tax expense (benefit) of $3.6 million and $(3.3) million , respectively, which represents an effective tax rate of (9.1)% and 5.2% , respectively. During the three and nine months ended September 30, 2018 , the Company recorded a tax expense (benefit) of $0.4 million and $(1.7) million , respectively, which represents an effective tax rate of 17.6% and 15.6% , respectively. As a result of the Merger, the Company recorded a full valuation allowance against all of its net U.S. federal and state deferred tax assets with the exception of $1.0 million of estimated state net operating losses (“NOL”). The initial recognition of this valuation allowance by the Company was reflected in the acquired identifiable assets and liabilities of BioScrip as of the Merger Date and did not impact the Company’s tax expense (benefit) for the nine months ended September 30, 2019. Due to the Company’s valuation allowance position as of the Merger Date, the Company recognized no tax benefit for post-Merger activity for the third quarter ended September 30, 2019 . In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences are deductible. The Company considers the scheduled reversal of deferred tax liabilities (including the effect in available carryback and carryforward periods), projected taxable income, and tax-planning strategies in making this assessment. On a quarterly basis, the Company evaluates all positive and negative evidence in determining if the valuation allowance is fairly stated. Based on the Company’s full valuation allowance as noted above, the Company’s tax expense for the three months ended September 30, 2019 of $3.6 million consists of quarterly tax liabilities attributable to specific state tax returns as well as the Company’s deferred tax expense recognized during the third quarter of 2019 prior to the Merger. The Company’s tax benefit for the nine months ended September 30, 2019 consists of a deferred tax benefit recognized by the Company prior to the establishment of its valuation allowance at the time of the Merger partially offset by estimated state tax liabilities.

(LOSS) EARNINGS PER SHARE

(LOSS) EARNINGS PER SHARE	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
(Loss) Earnings Per Share	(LOSS) EARNINGS PER SHARE The Company presents basic and diluted (loss) earnings per share for its common stock. Basic (loss) earnings per share is calculated by dividing the net (loss) income of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted (loss) earnings per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all dilutive potential common shares. As a result of the Merger, which has been accounted for as a reverse merger, all historical per share data and number of shares and equity awards were retroactively adjusted. The (loss) earnings is used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. Accordingly, the computation of diluted shares for the three and nine months ended September 30, 2019 excludes the effect of shares that would be issued in connection with stock options and restricted stock awards, as their inclusion would be anti-dilutive to the loss per share. There are no dilutive potential common shares for the three and nine months ended September 30, 2018 . The following table presents the Company’s basic and diluted (loss) earnings per share and shares outstanding (in thousands, except per share data): Three Months Ended Nine Months Ended 2019 2018 2019 2018 Numerator: Net (loss) income $ (42,794 ) $ 1,791 $ (60,109 ) $ (9,369 ) Denominator: Weighted average number of common shares outstanding 651,576 570,455 597,792 570,455 (Loss) Earnings per Common Share: (Loss) earnings per common share, basic and diluted $ (0.07 ) $ 0.00 $ (0.10 ) $ (0.02 )

LEASES

LEASES	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Leases	LEASES During the three and nine months ended September 30, 2019 , the Company incurred operating lease expenses of $7.4 million and $21.5 million , respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the condensed consolidated statements of comprehensive income (loss). As of September 30, 2019, the weighted-average remaining lease term was 5.3 years and the weighted-average discount rate was 5.41% . Operating leases mature as follows (in thousands): Fiscal Year Ending December 31 Minimum Payments 2019 $ 6,793 2020 24,733 2021 19,026 2022 14,021 2023 10,614 After 2024 24,582 Total lease payments $ 99,769 Less: Interest 15,805 Present value of lease liabilities $ 83,964 In addition, the Company had $0.8 million of financing leases outstanding at September 30, 2019 which mature over the next year. During the three months ended September 30, 2019 , the Company did not enter into any significant new operating or financing leases. As of September 30, 2019 , the Company did not have any significant operating or financing leases that had not yet commenced. During the three and nine months ended September 30, 2018 , the Company incurred rent expense of $4.5 million and $13.0 million , respectively, under ASC 840, Leases , which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income (loss).
Leases	LEASES During the three and nine months ended September 30, 2019 , the Company incurred operating lease expenses of $7.4 million and $21.5 million , respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the condensed consolidated statements of comprehensive income (loss). As of September 30, 2019, the weighted-average remaining lease term was 5.3 years and the weighted-average discount rate was 5.41% . Operating leases mature as follows (in thousands): Fiscal Year Ending December 31 Minimum Payments 2019 $ 6,793 2020 24,733 2021 19,026 2022 14,021 2023 10,614 After 2024 24,582 Total lease payments $ 99,769 Less: Interest 15,805 Present value of lease liabilities $ 83,964 In addition, the Company had $0.8 million of financing leases outstanding at September 30, 2019 which mature over the next year. During the three months ended September 30, 2019 , the Company did not enter into any significant new operating or financing leases. As of September 30, 2019 , the Company did not have any significant operating or financing leases that had not yet commenced. During the three and nine months ended September 30, 2018 , the Company incurred rent expense of $4.5 million and $13.0 million , respectively, under ASC 840, Leases , which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income (loss).

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	PROPERTY AND EQUIPMENT Property and equipment was as follows as of September 30, 2019 and December 31, 2018 (in thousands): September 30, 2019 December 31, 2018 Infusion pumps $ 24,786 $ 20,339 Equipment, furniture, and other 60,569 34,433 Leasehold improvements 84,675 61,302 Computer software, purchased and internally developed 34,500 29,668 Assets under development 4,585 5,447 209,115 151,189 Less accumulated depreciation 77,133 58,047 Property and equipment, net $ 131,982 $ 93,142 Depreciation expense is recorded within cost of revenue and operating expenses within the condensed consolidated statements of comprehensive income (loss), depending on the nature of the underlying fixed assets. The depreciation expense included in cost of revenue relates to revenue-generating assets, such as infusion pumps. The depreciation expense included in operating expenses is related to infrastructure items, such as furniture, computer and office equipment, and leasehold improvements. The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three and nine months ended September 30, 2019 and 2018 (in thousands): Three months ended September 30, Nine months ended September 30, 2019 2018 2019 2018 Depreciation expense in cost of revenue $ 1,384 $ 747 $ 2,855 $ 2,265 Depreciation expense in operating expenses 8,522 4,680 18,849 13,522 Total depreciation expense $ 9,906 $ 5,427 $ 21,704 $ 15,787

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	GOODWILL AND OTHER INTANGIBLE ASSETS Changes in the carrying amount of goodwill consists of the following activity for the three and nine months ended September 30, 2019 (in thousands): Three Months Ended September 30, 2019 June 30, 2019 - net book value $ 632,469 Acquisitions 786,904 September 30, 2019 - net book value $ 1,419,373 Nine Months Ended September 30, 2019 December 31, 2018 - net book value $ 632,469 Acquisitions 786,904 September 30, 2019 - net book value $ 1,419,373 Changes in the carrying amount of goodwill consists of the following activity for the three and nine months ended September 30, 2018 (in thousands): Three Months Ended September 30, 2018 June 30, 2018 - net book value $ 627,392 Acquisitions 4,492 September 30, 2018 - net book value $ 631,884 Nine Months Ended September 30, 2018 December 31, 2017 - net book value $ 627,392 Acquisitions 4,492 September 30, 2018 - net book value $ 631,884 The carrying amount and accumulated amortization of intangible assets consists of the following as of September 30, 2019 and December 31, 2018 (in thousands): September 30, 2019 December 31, 2018 Gross intangible assets: Referral sources $ 438,445 $ 257,792 Trademarks/names 44,702 32,000 Other amortizable intangible assets 379 4,151 Total gross intangible assets 483,526 293,943 Accumulated amortization: Referral sources (77,749 ) (63,353 ) Trademarks/names (10,657 ) (8,000 ) Other amortizable intangible assets (42 ) (2,877 ) Total accumulated amortization (88,448 ) (74,230 ) Total intangible assets, net $ 395,078 $ 219,713 Amortization expense for intangible assets was $7.5 million and $17.3 million for the three and nine months ended September 30, 2019 , respectively. Amortization expense for intangible assets was $4.9 million and $14.7 million for the three and nine months ended September 30, 2018 , respectively. The weighted average amortization period of intangible assets by class and in total as of September 30, 2019 are as follows: 17.1 years for referral sources, 4.1 years for trademarks/names, 1.5 years for other amortizable intangible assets, and 15.9 years for total intangible assets.

EQUITY-METHOD INVESTMENTS

EQUITY-METHOD INVESTMENTS	9 Months Ended
	Sep. 30, 2019
Equity Method Investments and Joint Ventures [Abstract]
Equity-Method Investments	EQUITY-METHOD INVESTMENTS The Company’s two equity-method investments totaled $16.1 million and $14.6 million as of September 30, 2019 and December 31, 2018 , respectively, and are included in other noncurrent assets in the accompanying condensed consolidated balance sheets. The Company’s related proportionate share of earnings is recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income (loss). For the three and nine months ended September 30, 2019 , the Company’s proportionate share of earnings in its investments was $0.8 million and $2.0 million , respectively. For the three and nine months ended September 30, 2018 , the Company’s proportionate share of earnings was $0.3 million and $0.7 million , respectively. Legacy Health Systems — The Company’s 50% ownership interest in this limited liability company, which provides infusion pharmacy services, expands the Company’s presence in the Portland, Oregon market. In 2005, Option Care’s initial cash investment in this joint venture was $1.3 million . The Company received a capital distribution from this investment of $0.5 million for the three and nine months ended September 30, 2019 . The Company did no t receive a capital distribution from this investment for the three or nine months ended September 30, 2018 . The following presents condensed financial information as of September 30, 2019 and December 31, 2018 and for the three and nine months ended September 30, 2019 and 2018 (in thousands). Consolidated statements of comprehensive income (loss) data: Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Net revenue $ 5,814 $ 5,572 $ 15,210 $ 15,728 Cost of revenue 4,083 3,853 10,882 11,132 Gross profit 1,731 1,719 4,328 4,596 Net income 670 402 1,177 1,225 Equity in net income 335 201 588 612 Consolidated balance sheet data: As of September 30, 2019 December 31, 2018 Current assets $ 6,358 $ 5,666 Noncurrent assets 4,072 3,403 Current liabilities 572 119 Noncurrent liabilities 740 8 Vanderbilt Health Services — The Company’s 50% ownership interest in this limited liability company, which provides infusion pharmacy services, expands the Company’s presence in the Nashville, Tennessee market. In 2009, Option Care contributed both cash and certain operating assets into the joint venture for a total initial investment of $1.1 million . The following presents condensed financial information as of September 30, 2019 and December 31, 2018 and for the three and nine months ended September 30, 2019 and 2018 (in thousands). Consolidated statements of comprehensive income (loss) data: Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Net revenue $ 9,638 $ 7,659 $ 28,701 $ 22,055 Cost of revenue 7,473 5,718 21,989 16,943 Gross profit 2,165 1,941 6,712 5,112 Net income 982 199 2,859 88 Equity in net income 491 100 1,430 44 Consolidated balance sheet data: As of September 30, 2019 December 31, 2018 Current assets $ 10,095 $ 6,517 Noncurrent assets 2,206 1,008 Current liabilities 1,116 192 Noncurrent liabilities 1,061 68

INDEBTEDNESS

INDEBTEDNESS	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Indebtedness	INDEBTEDNESS Long-term debt consisted of the following as of September 30, 2019 (in thousands): Principal Amount Discount Debt Issuance Costs Net Balance ABL Facility $ — $ — $ — $ — First Lien Term Loan 925,000 (8,681 ) (23,590 ) 892,729 Second Lien Notes 400,000 (11,876 ) (14,455 ) 373,669 $ 1,325,000 $ (20,557 ) $ (38,045 ) 1,266,398 Less: current portion (6,938 ) Total long-term debt $ 1,259,460 Long-term debt consisted of the following as of December 31, 2018 (in thousands): Principal Amount Discount Debt Issuance Costs Net Balance Previous Revolving Credit Facility $ — $ — $ — $ — Previous First Lien Term Loan 401,513 (1,062 ) (5,678 ) 394,773 Previous Second Lien Term Loan 150,000 — (5,398 ) 144,602 $ 551,513 $ (1,062 ) $ (11,076 ) 539,375 Less: current portion (4,150 ) Total long-term debt $ 535,225 Retired Debt Obligations — During 2015, Option Care entered into two credit arrangements administered by Bank of America, N.A. and U.S. Bank. The agreements provided for up to $645.0 million in senior secured credit facilities through an $80.0 million revolving credit facility (the “Previous Revolving Credit Facility”), a $415.0 million first lien term loan (the “Previous First Lien Term Loan”), and a $150.0 million second lien term loan (the “Previous Second Lien Term Loan”, and together with the Previous First Lien Term Loan, the “Previous Term Loans”, and the Previous Term Loans, together with the Previous Revolving Credit Facility, the “Previous Credit Facilities”). Amounts borrowed under the credit agreements were secured by substantially all of the assets of the Company. The Company incurred an original issue discount in conjunction with entering into the Previous First Lien Term Loan of $2.1 million , and also incurred an aggregate of $21.1 million in debt issuance costs to obtain the two credit agreements. These costs were recorded as a reduction to the carrying amount in the condensed consolidated balance sheets and were being amortized over the term of the related debt using the effective interest method for the Previous Term Loans and the straight-line method for the Previous Revolving Credit Facility. On August 6, 2019, the Company repaid the outstanding balance of Previous Term Loans and retired the outstanding Previous Credit Facilities by entering into two new credit arrangements and a notes indenture, described below under “New Debt Obligations”. At the time of repayment, the outstanding balance of the Previous First Lien Term Loan was $393.8 million , which was comprised of principal of $399.4 million , net of debt issuance costs of $0.9 million and deferred financing costs of $4.7 million . The balance of the Previous Second Lien Term Loan was $145.8 million , which was comprised of principal of $150.0 million , net of deferred financing costs of $4.2 million . Proceeds from the two new credit arrangements and notes indenture were also used, in part, to repay the outstanding debt of BioScrip as of the Merger Date of $575.0 million . The interest rate on the Previous First Lien Term Loan was 6.10% as of December 31, 2018 and the interest rate on the Previous Second Lien Term Loan was 11.15% as of December 31, 2018 . The weighted average interest rate paid on the Previous First Lien Term Loan was 6.06% and 6.20% for the three and nine months ended September 30, 2019, respectively, prior to the retirement of the debt obligations. The weighted average interest paid on the Previous Second Lien Term Loan was 11.02% and 11.36% for the three and nine months ended September 30, 2019 , respectively, prior to the retirement of the debt obligations. The weighted average interest rate paid on the Previous First Lien Term Loan was 5.83% and 6.38% for the three and nine months ended September 30, 2018 . The weighted average interest paid on the Previous Second Lien Term Loan was 11.09% and 10.68% for the three and nine months ended September 30, 2018 . New Debt Obligations — In conjunction with the Merger, the Company entered into an asset-based-lending revolving credit facility administered by Bank of America, N.A., as the administrative agent and a first lien term loan facility administered by Bank of America, N.A. and ACF Finco I LP, as joint lead arrangers and bookrunners. The Company also issued senior secured second lien PIK toggle floating rate notes due 2027 (the “Second Lien Notes”) under an indenture with Ankura Trust Company, LLC, as trustee and collateral agent for the Second Lien Notes. The two new credit agreements and the indenture were entered into on August 6, 2019 and provide for up to $1,475.0 million in senior secured credit facilities through a $150.0 million asset-based-lending revolving credit facility (the “ABL Facility”), a $925.0 million first lien term loan (the “First Lien Term Loan”, and together with the ABL Facility, the “Loan Facilities”), and a $400.0 million issuance of Second Lien notes. The ABL Facility provides for borrowings up to $150.0 million , which matures on August 6, 2024 . The ABL Facility bears interest at a per annum rate that is determined by the Company’s periodic selection of rate type, either the Base Rate or the Eurocurrency Rate. Interest on the ABL Facility is charged on Base Rate loans at Base Rate, as defined, plus 1.25% to 1.75% , depending on the historical excess availability as a percentage of the Line Cap, as defined in the ABL Facility credit agreement. Interest on the ABL Facility is charged on Eurocurrency Rate Loans at the Eurocurrency Rate, as defined, plus 2.25% to 2.75% , depending on the historical excess availability as a percentage of the Line Cap, as defined in the ABL Facility credit agreement. The ABL Facility contains commitment fees payable on the unused portion ranging from 0.25% to 0.375% , depending on various factors including the Company’s leverage ratio, type of loan and rate type, and letter of credit fees of 2.5% . Borrowings under the ABL Facility are secured by a first priority security interest in the Company’s and each of its subsidiaries’ inventory, accounts receivable, cash, deposit accounts and certain assets and property related thereto (the “ABL Priority Collateral”), in each case subject to certain exceptions, and a third priority security interest in the Term Loan Priority Collateral, as defined below. The Company had no outstanding borrowings under the ABL Facility at September 30, 2019 . The Company had $9.6 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the ABL of $140.4 million as of September 30, 2019 . The principal balance of the First Lien Term Loan is repayable in quarterly installments commencing in March 2020 of $2.3 million plus interest, with a final payment of all remaining outstanding principal due on August 6, 2026 . Interest on the First Lien Term Loan is payable monthly on Base Rate loans at Base Rate, as defined, plus 3.25% to 3.50% , depending on the Company’s leverage ratio. Interest is charged on Eurocurrency Rate loans at the Eurocurrency Rate, as defined, plus 4.25% to 4.50% , depending on the Company’s leverage ratio. The interest rate on the First Lien Term Loan was 6.61% as of September 30, 2019 . The weighted average interest rate incurred was 6.67% for the period August 6, 2019 through September 30, 2019 . Amounts borrowed under the First Lien Term Loan are secured by a first priority security interest in each of the Company’s subsidiaries’ capital stock (subject to certain exceptions) and substantially all of the Company’s property and assets (other than the ABL Priority Collateral), (the “Term Loan Priority Collateral”), in each case subject to certain exceptions, and a second priority security interest in the ABL Priority Collateral. The Second Lien Notes mature on August 6, 2027 . Interest on the Second Lien Notes is payable quarterly and is at the greater of 1% or the London Interbank Offered Rate (“LIBOR”), plus 8.75% . The Company elected to pay-in-kind the first quarterly interest payment, due in November 2019, which will result in the Company capitalizing the interest payment to the principal balance on the interest payment date. The interest rate on the Second Lien Notes was 10.89% as of September 30, 2019 . The weighted average interest incurred was 10.89% for the period August 6, 2019 through September 30, 2019 . The Company assessed whether the repayment of the Previous Term Loans and subsequent issuance of the First Lien Term Loan and the Second Lien Notes resulted in an insubstantial modification or an extinguishment of the existing debt for each loan in the syndication by grouping lenders as follows: (i) Lenders participating in both the Previous Credit Facilities and the new Loan Facilities and Second Lien Notes; (ii) previous lenders that exited; and (iii) new lenders. The Company determined that $226.7 million of the Previous First Lien Term Loan was extinguished and none of the Previous Second Lien Term Loan was extinguished, which is disclosed as an outflow from financing activities in the condensed consolidated statements of cash flows. The Company determined that $752.4 million of new debt was issued related to the First Lien Term Loan and $250.0 million of new debt was issued related to the Second Lien Notes, which is disclosed as an inflow from financing activities in the condensed consolidated statements of cash flows. In connection with the issuance of the First Lien Term Loan, the Second Lien Notes, and the ABL Facility, the Company incurred $59.1 million in debt issuance costs and third-party fees, of which $54.6 million was capitalized, $1.3 million was expensed as a component of other expense and $3.2 million was expensed as a loss on extinguishment as a component of other expense. Further, $21.3 million of the total fees incurred of $59.1 million was netted against the $981.1 million of proceeds from debt as a component of the cash flows from financing activities, $36.5 million was presented as deferred financing costs as a component of cash flows from financing activities, and the remaining $1.3 million was included in cash flows from operating activities. The Company recognized a loss on extinguishment of debt of $5.5 million , of which $3.2 million related to debt issue costs incurred with the issuance of the Loan Facilities and Second Lien Notes, as discussed above, and $2.3 million related to deferred financing fees on the Previous Credit Facilities, which were written off upon extinguishment. All remaining deferred financing fees related to the Previous Credit Facilities of $7.6 million were attributed to modified loans, which are capitalized and will be amortized over the remaining term of the Loan Facilities and Second Lien Notes. Long-term debt matures as follows (in thousands): Fiscal Year Ending December 31, Minimum Payments 2019 $ — 2020 9,250 2021 9,250 2022 9,250 2023 9,250 2024 and beyond 1,288,000 Total $ 1,325,000 During the three and nine months ended September 30, 2019 , the Company engaged in hedging activities to limit its exposure to changes in interest rates. See Note 12, Derivative Instruments , for further discussion. The following table presents the estimated fair values of the Company’s debt obligations as of September 30, 2019 (in thousands): Financial Instrument Carrying Value as of September 30, 2019 Markets for Identical Item (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) First Lien Term Loan $ 892,729 $ — $ 922,688 $ — Second Lien Notes 373,669 — — 394,653 Total debt instruments $ 1,266,398 $ — $ 922,688 $ 394,653 The following table sets forth the changes in Level 3 measurements for the nine months ended September 30, 2019 (in thousands): Level 3 Measurements Previous Term Loans fair value as of January 1, 2019 $ 551,882 Change in fair value (369 ) Repayments of debt principal (2,075 ) Retirements of Previous Term Loans (549,438 ) Issuance of Second Lien Notes as of August 6, 2019 388,000 Change in fair value 6,653 Second Lien Notes fair value as of September 30, 2019 $ 394,653 See Note 13, Fair Value Measurements , for further discussion.

DERIVATIVE INSTRUMENTS

DERIVATIVE INSTRUMENTS	9 Months Ended
	Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	DERIVATIVE INSTRUMENTS The Company uses derivative financial instruments for hedging and non-trading purposes to limit the Company’s exposure to increases in interest rates related to its variable interest rate debt. Use of derivative financial instruments in hedging programs subjects the Company to certain risks, such as market and credit risks. Market risk represents the possibility that the value of the derivative financial instrument will change. In a hedging relationship, the change in the value of the derivative financial instrument is offset to a great extent by the change in the value of the underlying hedged item. Credit risk related to a derivative financial instrument represents the possibility that the counterparty will not fulfill the terms of the contract. The notional, or contractual, amount of the Company’s derivative financial instruments is used to measure interest to be paid or received and does not represent the Company’s exposure due to credit risk. Credit risk is monitored through established approval procedures, including reviewing credit ratings when appropriate. During 2017 , Option Care entered into interest rate caps that reduce the risk of increased interest payments due to interest rates rising. The hedges offset the risk of rising interest rates through 2020 on the first $250.0 million of the Previous First Lien Term Loan. The interest rate caps perfectly offset the terms of the interest rates associated with the variable interest rate Previous First Lien Term Loan. Option Care entered into the interest rate caps as a cash flow hedge for a notional amount of $1.9 million . In April 2019, Option Care terminated its interest rate caps and received cash proceeds of $1.7 million , net of early termination fees. In conjunction with the termination of the interest rate caps, Option Care discontinued the hedge accounting associated with the interest rate caps. In August 2019, the Company entered into interest rate swap agreements that reduce the variability in the interest rates on the newly-issued debt obligations. The first interest rate swap for $925.0 million notional was effective in August 2019 with $911.1 million designated as a cash flow hedge against the underlying interest rate on the First Lien Term Loan interest payments indexed to one-month LIBOR through August 2021. In accordance with ASU 2017-12, Targeted Improvements to Accounting for Hedges , the Company has determined that the hedges are perfectly effective. The remaining $13.9 million notional amount of the interest rate swap is not designated as a hedging instrument. The second interest rate swap of $400.0 million notional will become effective in November 2019 and will be designated as a cash flow hedge against the underlying interest rate on the Second Lien Notes interest payments indexed to three-month LIBOR through November 2020. The interest rate designated as a cash flow hedge is expected to be perfectly effective at offsetting the terms of the interest rates associated with the Company’s variable interest rate Second Lien Notes. The following table summarizes the amount and location of the Company’s derivative instruments in the condensed consolidated balance sheets (in thousands): Fair value - Derivatives in asset position Derivative Balance Sheet Caption September 30, 2019 December 31, 2018 Interest rate caps designated as cash flow hedges Prepaids and other current assets $ — $ 2,627 Total derivatives $ — $ 2,627 Fair value - Derivatives in liability position Derivative Balance Sheet Caption September 30, 2019 December 31, 2018 Interest rate swaps designated as cash flow hedges Other non-current liabilities $ 7,883 $ — Interest rate swaps not designated as hedges Other non-current liabilities 120 — Total derivatives $ 8,003 $ — The gain and loss associated with the changes in the fair value of the effective portion of the hedging instrument are recorded into other comprehensive (loss) income. The gain and loss associated with the changes in the fair value of the $13.9 million notional amount not designated as a hedging instrument are recognized in net income through interest expense. The following table presents the pre-tax gains (losses) from derivative instruments recognized in other comprehensive (loss) income in the Company’s condensed consolidated statements of comprehensive income (loss) (in thousands): Three months ended September 30, Nine months ended September 30, Derivative 2019 2018 2019 2018 Interest rate caps designated as cash flow hedges $ (398 ) $ 221 $ (1,103 ) $ 2,165 Interest rate swaps designated as cash flow hedges (7,883 ) — (7,883 ) — $ (8,281 ) $ 221 $ (8,986 ) $ 2,165 The following table presents the amount and location of pre-tax income (loss) recognized in the Company’s condensed consolidated statement of comprehensive income (loss) related to the Company’s derivative instruments (in thousands): Three months ended September 30, Nine months ended September 30, Derivative Income Statement Caption 2019 2018 2019 2018 Interest rate caps designated as cash flow hedges Interest expense $ 269 $ 89 $ (125 ) $ 158 Interest rate swaps designated as cash flow hedges Interest expense 129 — 129 — Interest rate swaps not designated as hedges Interest expense (118 ) — (118 ) — $ 280 $ 89 $ (114 ) $ 158 The Company expects to reclassify $5.8 million of total interest rate costs from accumulated other comprehensive loss against interest expense during the next 12 months.

FAIR VALUE MEASURMENTS

FAIR VALUE MEASURMENTS	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
FAIR VALUE MEASURMENTS	FAIR VALUE MEASUREMENTS Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows: • Level 1 — Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities. • Level 2 — Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. • Level 3 — Inputs to the fair value measurement are unobservable inputs or valuation techniques. While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. First Lien Term Loan : The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs) See Note 11, Indebtedness , for further discussion on the carrying amount and fair value of the First Lien Term Loan. Second Lien Notes : The fair value of the Second Lien Notes is derived from a cash flow model that discounted the cash flows based on market interest rates (Level 3 inputs) See Note 11, Indebtedness , for further discussion on the carrying amount and fair value of the Second Lien Notes. Interest rate swaps : The fair values of interest rate swaps are derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 12, Derivative Instruments , for further discussion on the fair value of interest rate swaps. Interest rate caps : The fair values of interest rate caps are derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. In April 2019, Option Care terminated its interest rate caps. The total investment in interest rate caps as Level 2 assets was $0 million and $2.6 million as of September 30, 2019 and December 31, 2018 , respectively. See Note 12, Derivative Instruments , for further discussion on the fair value of interest rate caps. There were no other assets or liabilities measured at fair value at September 30, 2019 or December 31, 2018 .

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries, and similar actions by governmental authorities, arising in the normal course of the Company’s business. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company may also be involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property, and other matters. Gain contingencies, if any, are recognized when they are realized. The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s condensed consolidated balance sheets. However, substantial unanticipated verdicts, fines, and rulings may occur. As a result, the Company may from time to time incur judgments, enter into settlements, or revise expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.

STOCK-BASED INCENTIVE COMPENSAT

STOCK-BASED INCENTIVE COMPENSATION	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Incentive Compensation	STOCK-BASED INCENTIVE COMPENSATION Equity Incentive Plans — Under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”), approved at the annual meeting by the BioScrip stockholders on May 3, 2018, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors. The 2018 plan is administered by the Company’s Compensation Committee, a standing committee of the Board of Directors. A total of 16,406,939 shares of common stock were initially authorized for issuance under the 2018 Plan. Stock Options — During the three and nine months ended September 30, 2019 , the Company recognized compensation expense related to stock options of $0.5 million . The Company did not recognize any compensation expense related to stock options prior to the Merger. Restricted Stock — During the three and nine months ended September 30, 2019 , the Company recognized compensation expense related to restricted stock awards of $1.7 million . The Company did not recognize any compensation expense related to restricted stock awards prior to the Merger. HC I Incentive Units — During the three and nine months ended September 30, 2019 , the Company recognized compensation expense related to HC I incentive units of $0.5 million and $1.7 million , respectively. During the three and nine months ended September 30, 2018 , the Company recognized compensation expense related to HC I incentive units of $0.6 million and $1.7 million , respectively. See Note 17, Related-Party Transactions , for further discussion of this management equity ownership plan.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Stockholders' Equity	STOCKHOLDERS’ EQUITY 2017 Warrants — Prior to the Merger, BioScrip issued warrants to certain debt holders pursuant to a Warrant Purchase Agreement dated as of June 29, 2017. In conjunction with the Merger, the 2017 Warrants were amended to entitle the purchasers of the warrants to purchase 8.3 million shares of common stock. The 2017 Warrants have a 10 -year term and an exercise price of $2.00 per share, and may be exercised by payment of the exercise price in cash or surrender of shares of common stock into which the 2017 Warrants are being converted in an aggregate amount sufficient to pay the exercise price. The 2017 Warrants were assumed by the Company in conjunction with the Merger. The 2017 Warrants are classified as equity instruments, and the fair value of these warrants of $14.1 million was recorded in paid-in capital as of the Merger Date. 2015 Warrants — Prior to the Merger, BioScrip issued warrants pursuant to a Common Stock Warrant Agreement dated as of March 9, 2015 which entitle the holders to purchase 3.7 million shares of common stock. The 2015 Warrants have a 10 -year term and have exercise prices in a range of $5.17 per share to $6.45 per share. The 2015 Warrants were assumed by the Company in conjunction with the Merger and are classified as equity instruments, and the fair value of these warrants of $4.6 million was recorded in paid in capital as of the Merger Date. Home Solutions Restricted Stock — In conjunction with BioScrip’s 2016 acquisition of Home Solutions, Inc., 7.1 million restricted shares of common stock were issued, of which 3.1 million of these units vest upon the closing price of the Company’s common stock averaging at or above $4.00 per share over 20 consecutive trading days prior to December 31, 2019 and 4.0 million of these units vest upon the closing price of the Company’s common stock averaging at or above $5.00 per share over 20 consecutive trading days prior to December 31, 2019 . The restricted stock expires on December 31, 2019 . As discussed in Note 1, Nature of Operations and Presentation of Financial Statements , 28,193,428 common shares issued to HC I in conjunction with the Merger are held in escrow to prevent dilution related to the vesting of the Home Solutions restricted stock. In the event the Home Solutions restricted stock expires unvested, the 28,193,428 common shares held in escrow will be returned to the Company and canceled. Treasury Stock — During the three and nine months ended September 30, 2019 , 1,146,065 shares were surrendered to satisfy tax withholding obligations on the exercise of stock options and the vesting of restricted stock awards with a cost basis of $2.4 million . At September 30, 2019 , the Company held 1,736,220 shares of treasury stock. No treasury stock existed prior to the Merger. Preferred Stock — In conjunction with the Merger, all legacy BioScrip preferred stock was settled, and no preferred stock is outstanding as of September 30, 2019 . There was no preferred stock existing as of December 31, 2018 .

RELATED-PARTY TRANSACTIONS

RELATED-PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Related-Party Transactions	RELATED-PARTY TRANSACTIONS Management Equity Ownership Plan — In October 2015, HC I implemented an equity ownership and incentive plan for certain officers and employees of Option Care. The officers were able to purchase membership units in HC I and could fund a portion of the purchase with a loan from Option Care. These loans were treated as a shareholder contribution in Option Care. For the nine months ended September 30, 2019 and 2018 , $0 and $0.4 million , respectively, were credited to paid-in capital related to HC I membership units purchased with a loan from Option Care. There were no shareholder redemptions during the three months ended September 30, 2019 . During the nine months ended September 30, 2019 , shareholder redemptions totaled $2.4 million , comprised of a cash distribution to HC I of $2.0 million and notes redeemed of $0.4 million . During the three months ended September 30, 2019 , prior to the Merger, Option Care sold its notes receivable from management, along with all accrued interest expense, to a third-party bank. Option Care received cash proceeds of $1.3 million , which represented payment of $1.1 million in outstanding notes receivable from management and payment of $0.2 million in accrued interest expense. Notes receivable from management of $0 and $1.6 million remained outstanding as of September 30, 2019 and December 31, 2018 , respectively. The notes receivable from management and associated interest receivable are recorded in management notes receivable as a reduction to equity on the Company’s condensed consolidated balance sheets as of December 31, 2018 . Transactions with Equity-Method Investees — The Company provides management services to its joint ventures such as accounting, invoicing and collections in addition to day-to-day managerial support of the operations of the businesses. The Company recorded management fee income of $0.6 million and $1.8 million for the three and nine months ended September 30, 2019 , respectively. The Company recorded management fee income of $0.6 million and $1.6 million for the three and nine months ended September 30, 2018 , respectively. Management fees are recorded in net revenues in the accompanying unaudited condensed consolidated statements of comprehensive income (loss). The Company had amounts due to its joint ventures of $3.1 million as of September 30, 2019 . The Company also had amounts due to its joint ventures of $0.9 million and amounts due from its joint ventures of $0.1 million as of December 31, 2018 . These payables were included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheets and these receivables were included in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets. These balances primarily relate to cash collections received by the Company on behalf of the joint ventures, offset by certain pharmaceutical inventories purchased by the Company on behalf of the joint ventures.

SUBSEQUENT EVENT

SUBSEQUENT EVENT	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Event	SUBSEQUENT EVENT There were no subsequent events occurring from September 30, 2019 through November 6, 2019, the date the financial statements were available to be issued.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation — The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2018 audited consolidated financial statements, including the notes thereto, as presented in the definitive merger proxy with the Securities and Exchange Commission filed on June 26, 2019.
Principles of Consolidation	Principles of Consolidation — The Company’s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. The BioScrip results have been included in the consolidated financial results since the Merger Date. All intercompany transactions and balances are eliminated in consolidation.
Leases	Leases — The Company has lease agreements for facilities, warehouses, office space and property and equipment. Effective as of January 1, 2019, at the inception of a contract, the Company determines if the contract is a lease or contains an embedded lease arrangement. Operating leases are included in the operating lease right-of-use asset (“ROU asset”) and operating lease liabilities in the condensed consolidated financial statements. ROU assets, which represent the Company’s right to use the leased assets, and operating lease liabilities, which represent the present value of unpaid lease payments, are both recognized by the Company at the lease commencement date. The Company utilizes its estimated incremental borrowing rate at the lease commencement date to determine the present value of unpaid lease obligations. The rates were estimated primarily using a methodology dependent on the Company’s financial condition, creditworthiness, and availability of certain observable data. In particular, the Company considered its actual cost of borrowing for collateralized loans and its credit rating, along with the corporate bond yield curve in estimating its incremental borrowing rates. ROU assets are recorded as the amount of operating lease liability, adjusted for prepayments, accrued lease payments, initial direct costs, lease incentives, and impairment of the ROU asset. Tenant improvement allowances used to fund leasehold improvements are recognized when earned and reduce the related ROU asset. Tenant improvement allowances are amortized through the ROU asset as a reduction of expense over the term of the lease. Leases may contain rent escalations, however the Company recognizes the lease expense on a straight-line basis over the expected lease term. The Company reviews the terms of any lease renewal options to determine if it is reasonably certain that the renewal options will be exercised. The Company has determined that the expected lease term is typically the minimum non-cancelable period of the lease. The Company has lease agreements that contain both lease and non-lease components, which the Company has elected to account for as a single lease component for all asset classes. Leases with an initial term of 12 months or less are not recorded on the condensed consolidated balance sheet and are expensed on a straight-line basis over the term of the lease. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.
Stock Based Incentive Compensation	Stock Based Incentive Compensation — The Company accounts for stock-based incentive compensation expense in accordance with Accounting Standards Codification (“ASC”) Topic 718, Compensation-Stock Compensation (“ASC 718”). Stock-based incentive compensation expense is based on the grant date fair value. The Company estimates the fair value of stock option awards using a Black-Scholes option pricing model and the fair value of restricted stock unit awards using the closing price of the Company’s common stock on the grant date. For awards with a service-based vesting condition, the Company recognizes expense on a straight-line basis over the service period of the award. For awards with performance-based vesting conditions, the Company will recognize expense when it is probable that the performance-based conditions will be met. When the Company determines that it is probable that the performance-based conditions will be met, a cumulative catch-up of expense will be recorded as if the award had been vesting on a straight-line basis from the award date. The award will continue to be expensed on a straight-line basis through the remainder of the vesting period and will be updated if the Company determines that there has been a change in the probability of achieving the performance-based conditions. The Company records the impact of forfeited awards in the period in which the forfeiture occurs. Prior to the Merger, HCI issued incentive units to certain employees of Option Care, who remained employees of the Company following the Merger. In accordance with ASC 718, the Company recognizes compensation expense on a straight-line basis over the shorter of the vesting period of the award or the employee’s expected eligibility date. HC I also issued equity incentive units to certain members of the Option Care Board of Directors, who remained members of the Board of Directors following the Merger. In accordance with ASC Topic 505, Equity Based Payment to Non-Employees , expense was recognized at grant date. See Note 15, Stock-Based Incentive Compensation , for a further discussion of equity incentive plans.
Concentrations of Business Risk	Concentrations of Business Risk — The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 15% and 13% for the three and nine months ended September 30, 2019 , respectively. Revenue related to the Company’s largest payer was approximately 16% and 14% for the three and nine months ended September 30, 2018 , respectively. For the three and nine months ended September 30, 2019 , approximately 13% and 12% , respectively, of the Company’s revenue was reimbursable through Medicare and Medicaid. For the three and nine months ended September 30, 2018 , approximately 11% and 11% , respectively, of the Company’s revenue was reimbursable through Medicare and Medicaid. As of September 30, 2019 and December 31, 2018 , respectively, approximately 14% and 13% , respectively, of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term. Concentration of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. For the three and nine months ended September 30, 2019 , approximately 69% and 72% , respectively, of the Company’s pharmaceutical and medical supply purchases were from three vendors. For the three and nine months ended September 30, 2018 , approximately 75% and 76% , respectively, of the Company’s pharmaceutical and medical supply purchases were from three vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company’s financial condition or operating results.
Recent Accounting Pronouncements	Recently-Adopted Accounting Pronouncements — In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, Leases , intended to improve financial reporting about leasing transactions. The new guidance requires entities that lease assets to recognize on their balance sheets the ROU assets and lease liabilities for the rights and obligations created by those leases and to disclose key information about leasing arrangements. ASU 2016-02 is effective for interim and annual periods beginning after December 15, 2018 for public entities and certain not-for-profits. The Company adopted the standard as of January 1, 2019. ASU 2016-02 allows for an optional transition method, which was elected by the Company, and permits the application of the standard as of the effective date without requiring the standard to be applied to the comparative periods presented in the unaudited condensed consolidated financial statements. The Company elected the transition package of three practical expedients allowed by ASU 2016-02, which allows the Company not to reassess prior conclusions about lease identification, lease classification and initial, direct costs. The Company did not elect the practical expedient to use hindsight and, accordingly, the initial lease term did not differ under the new standard versus prior accounting practice. The Company also made a policy election not to apply this standard to any leases with a term of 12 months or less. Adoption of ASU 2016-02 resulted in the Company recording an operating lease liability of $67.0 million and a corresponding ROU asset of $59.9 million in the unaudited condensed consolidated balance sheet as of January 1, 2019. See Note 7, Leases , for further discussion on leases. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers . The ASU requires that an entity recognizes revenue to depict the transfer of promised goods or services to a customer in an amount that reflects the consideration to which the Company expects to be entitled in exchange for these goods or services. ASU 2014-09 is effective for interim and annual reporting periods beginning after December 15, 2017 for public entities and certain not-for-profits. The Company adopted the standard as of January 1, 2018. ASU 2014-09 allows for a modified retrospective approach upon adoption, which was elected by the Company, and permits application of the standard only to contracts that are not completed at the adoption date with no adjustment to the comparative periods presented in the unaudited condensed consolidated financial statements. The Company also elected the practical expedient for the portfolio approach, allowing contracts with similar characteristics and impacts to the financial statements to be evaluated together. ASU 2014-09 requires the Company to recognize revenue as the amount of cash that is ultimately expected to be collected, which resulted in the Company treating its previously-reported provision for doubeful accounts as an implicit price concession and a reduction to revenue. Other than the treatment of bad debt expense, the adoption of this standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements. See Note 4, Revenue , for further discussion on revenue. In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting . ASU 2019-09 modifies when a change to the terms or conditions of share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the fair value, vesting condition, or the classification of the award is not the same immediately before and after a change to the terms and conditions of the award. The effective date for ASU 2017-09 is for annual or interim periods beginning after December 15, 2017. The Company adopted the standard as of January 1, 2018. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements. Recent Accounting Pronouncements — In June 2016, the FASB issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which requires measurement and recognition of expected credit losses for financial assets held. The Amendments in ASU 2016-13 eliminate the probable threshold for initial recognition of a credit loss in current GAAP and reflect an entity’s current estimate of all expected credit losses. ASU 2016-13 is effective for interim and annual reporting periods beginning after December 15, 2019, and is to be applied using a modified retrospective transition method. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
Revenue	Net revenue is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services. Revenues are from government payers, commercial payers, and patients for goods and services provided and are based on a gross price based on payer contracts, fee schedules, or other arrangements less any implicit price concessions. Due to the nature of the health care industry and the reimbursement environment in which the Company operates, certain estimates are required to record revenue and accounts receivable at their net realizable values at the time goods or services are provided. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. The Company assesses the expected consideration to be received at the time of patient acceptance based on the verification of the patient’s insurance coverage, historical information with the patient, similar patients, or the payer. Performance obligations are determined based on the nature of the services provided by the Company. The majority of the Company’s performance obligations are to provide infusion services to deliver medicine, nutrients, or fluids directly into the body. The Company provides a variety of therapies to patients. For infusion-related therapies, the Company frequently provides multiple deliverables of pharmaceutical drugs and related nursing services. After applying the criteria from ASC 606, the Company concluded that multiple performance obligations exist in its contracts with its customers. Revenue is allocated to each performance obligation based on relative standalone price, determined based on reimbursement rates established in the third-party payer contracts. Pharmaceutical drug revenue is recognized at the time the pharmaceutical drug is delivered to the patient, and nursing revenue is recognized on the date of service. The Company's outstanding performance obligations relate to contracts with a duration of less than one year. Therefore, the Company has elected to apply the practical expedient provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. Any unsatisfied or partially unsatisfied performance obligations at the end of a reporting period are generally completed prior to the patient being discharged. On January 1, 2018, the Company adopted ASC 606, Revenue from Contracts with Customers using the modified retrospective approach applied to those contracts that were not completed as of that date. The Company did not record a cumulative catch-up adjustment, as the timing and measurement of revenue for the Company’s customers is similar to its prior revenue recognition model. ASC 606 requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to in exchange for those goods or services. ASC 606 requires application of a five-step model to determine when to recognize revenue and at what amount. The revenue standard applies to all contracts with customers and revenues are to be recognized when control of the promised goods or services is transferred to the Company’s patients in an amount that reflects consideration expected to be received in exchange for those goods or services.
Fair Value Measurements	FAIR VALUE MEASUREMENTS Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows: • Level 1 — Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities. • Level 2 — Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. • Level 3 — Inputs to the fair value measurement are unobservable inputs or valuation techniques. While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. First Lien Term Loan : The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs) See Note 11, Indebtedness , for further discussion on the carrying amount and fair value of the First Lien Term Loan. Second Lien Notes : The fair value of the Second Lien Notes is derived from a cash flow model that discounted the cash flows based on market interest rates (Level 3 inputs) See Note 11, Indebtedness , for further discussion on the carrying amount and fair value of the Second Lien Notes. Interest rate swaps : The fair values of interest rate swaps are derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 12, Derivative Instruments , for further discussion on the fair value of interest rate swaps. Interest rate caps : The fair values of interest rate caps are derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers.

BUSINESS ACQUISITIONS (Tables)

BUSINESS ACQUISITIONS (Tables)	9 Months Ended
	Sep. 30, 2019
Business Combinations [Abstract]
Schedule of Consideration Exchanged	Under the acquisition method of accounting, the calculation of total consideration exchanged is as follows (in thousands): Amount Number of BioScrip common shares outstanding at time of the Merger 129,181 Common shares issued to warrant and preferred stockholders at time of the Merger 3,458 Total shares of BioScrip common stock outstanding at time of the Merger 132,639 BioScrip share price as of August 6, 2019 $ 2.67 Fair value of common shares $ 354,146 Fair value of share-based instruments $ 32,898 Cash paid in conjunction with the Merger included in purchase consideration $ 714,957 Fair value of total consideration transferred $ 1,102,001 Less: cash acquired $ 14,787 Fair value of total consideration acquired, net of cash acquired $ 1,087,214
Schedule of Acquired Identifiable Assets and Assumed Liabilities	The following is a preliminary estimate of the allocation of the consideration transferred to acquired identifiable assets and assumed liabilities, net of cash acquired, in the Merger as of August 6, 2019 (in thousands): Amount Accounts receivable, net (1) $ 97,163 Inventories (2) 19,683 Property and equipment, net (3) 49,697 Intangible assets, net (4) 193,712 Deferred tax assets, net of deferred tax liabilities (5) 26,731 Operating lease right-of-use asset (6) 22,378 Operating lease liability (6) (28,897 ) Accounts payable (7) (61,420 ) Other assumed liabilities, net of other acquired assets (7) (18,737 ) Total acquired identifiable assets and liabilities 300,310 Goodwill (8) 786,904 Total consideration transferred $ 1,087,214 (1) Management has valued accounts receivables based on the estimated future collectability of the receivables portfolio, which approximates fair value. (2) Inventories are stated at fair value as of the Merger Date. (3) The fair value of the property and equipment was determined based upon the best and highest use of the property with final values determined based upon an analysis of the cost, sales comparison, and income capitalization approaches for each property appraised. (4) The preliminary allocation of consideration exchanged to intangible assets acquired is as follows (in thousands): Fair Value Weighted Average Estimated Life (in years) Trademarks/Names $ 12,681 2 Patient referral sources 180,652 20 Licenses 379 1.5 Total intangible assets, net $ 193,712 18.8 The Company preliminarily valued these intangibles utilizing the multi-period excess earnings method, a form of the income approach. (5) Net deferred tax assets represented the expected future tax consequences of temporary differences between the fair values of the assets acquired and liabilities assumed and their tax bases. See Note 5, Income Taxes , for additional discussion of the Company’s combined income tax position subsequent to the Merger. (6) The fair value of the operating lease liability and corresponding right-of-use asset (current and long-term) was based on current market rates available to the Company. (7) Accounts payable as well as certain other current and non-current assets and liabilities are stated at fair value as of the Merger Date. (8) The Merger preliminarily resulted in $786.9 million of goodwill, which is attributable to cost synergies resulting from procurement and operational efficiencies and elimination of duplicative administrative costs. The goodwill created in the Merger is not expected to be deductible for tax purposes.
Schedule of Allocation of Consideration to Intangible Assets Acquired	The preliminary allocation of consideration exchanged to intangible assets acquired is as follows (in thousands): Fair Value Weighted Average Estimated Life (in years) Trademarks/Names $ 12,681 2 Patient referral sources 180,652 20 Licenses 379 1.5 Total intangible assets, net $ 193,712 18.8
Schedule of Pro Forma Financial Information	Assuming BioScrip had been acquired as of January 1, 2018, and the results of BioScrip had been included in operations beginning on January 1, 2018, the following tables provide estimated unaudited pro forma results of operations for the three and nine months ended September 30, 2019 and 2018 (in thousands). The estimated pro forma net income adjusts for the effect of fair value adjustments related to the Merger, transaction costs and other non-recurring costs directly attributable to the Merger and the impact of the additional debt to finance the Merger. Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Net revenue $ 690,350 $ 674,890 $ 2,034,582 $ 1,959,395 Net loss (18,686 ) (7,919 ) (54,181 ) (59,670 )

REVENUE (Tables)

REVENUE (Tables)	9 Months Ended
	Sep. 30, 2019
Revenue from Contract with Customer [Abstract]
Schedule of the Impact of Adoption of Standards	Adoption of the standard impacted the Company’s results as follows (in thousands): Prior to ASC 606 Adoption Adjustments for ASC 606 Subsequent to ASC 606 Adoption As of September 30, 2019 Condensed Consolidated Balance Sheets Accounts receivable, net $ 336,303 $ — $ 336,303 Nine Months Ended September 30, 2019 Condensed Consolidated Statement of Comprehensive Income (Loss) Net revenue $ 1,644,903 $ (55,265 ) $ 1,589,638 Provision for doubtful accounts (55,265 ) 55,265 — Operating loss (14,600 ) — (14,600 ) Condensed Consolidated Statements of Cash Flows Changes in operating cash flows: Accounts receivable, net 71,029 — 71,029 As of December 31, 2018 Condensed Consolidated Balance Sheets Accounts receivable, net $ 310,169 $ — $ 310,169 Nine Months Ended September 30, 2018 Condensed Consolidated Statement of Comprehensive Income (Loss) Net revenue $ 1,479,058 $ (44,997 ) $ 1,434,061 Provision for doubtful accounts (44,997 ) 44,997 — Operating Income 24,721 — 24,721 Condensed Consolidated Statements of Cash Flows Changes in operating cash flows: Accounts receivable, net (32,483 ) — (32,483 )
Schedule of Net Revenue Earned by Category of Payer	The following table sets forth the net revenue earned by category of payer for the three and nine months ended September 30, 2019 and 2018 (in thousands): Three Months Ended Nine Months Ended 2019 2018 2019 2018 Commercial payers $ 525,927 $ 428,873 $ 1,373,481 $ 1,256,109 Government payers 80,280 56,511 194,875 160,939 Patients 9,673 8,544 21,282 17,013 Net revenue $ 615,880 $ 493,928 $ 1,589,638 $ 1,434,061

(LOSS) EARNINGS PER SHARE (Tabl

(LOSS) EARNINGS PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Loss Per Share	The following table presents the Company’s basic and diluted (loss) earnings per share and shares outstanding (in thousands, except per share data): Three Months Ended Nine Months Ended 2019 2018 2019 2018 Numerator: Net (loss) income $ (42,794 ) $ 1,791 $ (60,109 ) $ (9,369 ) Denominator: Weighted average number of common shares outstanding 651,576 570,455 597,792 570,455 (Loss) Earnings per Common Share: (Loss) earnings per common share, basic and diluted $ (0.07 ) $ 0.00 $ (0.10 ) $ (0.02 )

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Maturities of Lease Liabilities, Operating	eases mature as follows (in thousands): Fiscal Year Ending December 31 Minimum Payments 2019 $ 6,793 2020 24,733 2021 19,026 2022 14,021 2023 10,614 After 2024 24,582 Total lease payments $ 99,769 Less: Interest 15,805 Present value of lease liabilities $ 83,964
Maturities of Lease Liabilities, Financing	eases mature as follows (in thousands): Fiscal Year Ending December 31 Minimum Payments 2019 $ 6,793 2020 24,733 2021 19,026 2022 14,021 2023 10,614 After 2024 24,582 Total lease payments $ 99,769 Less: Interest 15,805 Present value of lease liabilities $ 83,964

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment was as follows as of September 30, 2019 and December 31, 2018 (in thousands): September 30, 2019 December 31, 2018 Infusion pumps $ 24,786 $ 20,339 Equipment, furniture, and other 60,569 34,433 Leasehold improvements 84,675 61,302 Computer software, purchased and internally developed 34,500 29,668 Assets under development 4,585 5,447 209,115 151,189 Less accumulated depreciation 77,133 58,047 Property and equipment, net $ 131,982 $ 93,142 The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three and nine months ended September 30, 2019 and 2018 (in thousands): Three months ended September 30, Nine months ended September 30, 2019 2018 2019 2018 Depreciation expense in cost of revenue $ 1,384 $ 747 $ 2,855 $ 2,265 Depreciation expense in operating expenses 8,522 4,680 18,849 13,522 Total depreciation expense $ 9,906 $ 5,427 $ 21,704 $ 15,787

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of the Carrying Amount of Goodwill	Changes in the carrying amount of goodwill consists of the following activity for the three and nine months ended September 30, 2019 (in thousands): Three Months Ended September 30, 2019 June 30, 2019 - net book value $ 632,469 Acquisitions 786,904 September 30, 2019 - net book value $ 1,419,373 Nine Months Ended September 30, 2019 December 31, 2018 - net book value $ 632,469 Acquisitions 786,904 September 30, 2019 - net book value $ 1,419,373 Changes in the carrying amount of goodwill consists of the following activity for the three and nine months ended September 30, 2018 (in thousands): Three Months Ended September 30, 2018 June 30, 2018 - net book value $ 627,392 Acquisitions 4,492 September 30, 2018 - net book value $ 631,884 Nine Months Ended September 30, 2018 December 31, 2017 - net book value $ 627,392 Acquisitions 4,492 September 30, 2018 - net book value $ 631,884
Schedule of Carrying Amount and Accumulated Amortization of Intangible Assets	The carrying amount and accumulated amortization of intangible assets consists of the following as of September 30, 2019 and December 31, 2018 (in thousands): September 30, 2019 December 31, 2018 Gross intangible assets: Referral sources $ 438,445 $ 257,792 Trademarks/names 44,702 32,000 Other amortizable intangible assets 379 4,151 Total gross intangible assets 483,526 293,943 Accumulated amortization: Referral sources (77,749 ) (63,353 ) Trademarks/names (10,657 ) (8,000 ) Other amortizable intangible assets (42 ) (2,877 ) Total accumulated amortization (88,448 ) (74,230 ) Total intangible assets, net $ 395,078 $ 219,713

EQUITY-METHOD INVESTMENTS (Tabl

EQUITY-METHOD INVESTMENTS (Tables)	9 Months Ended
	Sep. 30, 2019
Equity Method Investments and Joint Ventures [Abstract]
Schedule of Condensed Financial Information of Equity Method Investments	The following presents condensed financial information as of September 30, 2019 and December 31, 2018 and for the three and nine months ended September 30, 2019 and 2018 (in thousands). Consolidated statements of comprehensive income (loss) data: Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Net revenue $ 5,814 $ 5,572 $ 15,210 $ 15,728 Cost of revenue 4,083 3,853 10,882 11,132 Gross profit 1,731 1,719 4,328 4,596 Net income 670 402 1,177 1,225 Equity in net income 335 201 588 612 Consolidated balance sheet data: As of September 30, 2019 December 31, 2018 Current assets $ 6,358 $ 5,666 Noncurrent assets 4,072 3,403 Current liabilities 572 119 Noncurrent liabilities 740 8 The following presents condensed financial information as of September 30, 2019 and December 31, 2018 and for the three and nine months ended September 30, 2019 and 2018 (in thousands). Consolidated statements of comprehensive income (loss) data: Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Net revenue $ 9,638 $ 7,659 $ 28,701 $ 22,055 Cost of revenue 7,473 5,718 21,989 16,943 Gross profit 2,165 1,941 6,712 5,112 Net income 982 199 2,859 88 Equity in net income 491 100 1,430 44 Consolidated balance sheet data: As of September 30, 2019 December 31, 2018 Current assets $ 10,095 $ 6,517 Noncurrent assets 2,206 1,008 Current liabilities 1,116 192 Noncurrent liabilities 1,061 68

INDEBTEDNESS (Tables)

INDEBTEDNESS (Tables)	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Summary of Debt	Long-term debt consisted of the following as of September 30, 2019 (in thousands): Principal Amount Discount Debt Issuance Costs Net Balance ABL Facility $ — $ — $ — $ — First Lien Term Loan 925,000 (8,681 ) (23,590 ) 892,729 Second Lien Notes 400,000 (11,876 ) (14,455 ) 373,669 $ 1,325,000 $ (20,557 ) $ (38,045 ) 1,266,398 Less: current portion (6,938 ) Total long-term debt $ 1,259,460 Long-term debt consisted of the following as of December 31, 2018 (in thousands): Principal Amount Discount Debt Issuance Costs Net Balance Previous Revolving Credit Facility $ — $ — $ — $ — Previous First Lien Term Loan 401,513 (1,062 ) (5,678 ) 394,773 Previous Second Lien Term Loan 150,000 — (5,398 ) 144,602 $ 551,513 $ (1,062 ) $ (11,076 ) 539,375 Less: current portion (4,150 ) Total long-term debt $ 535,225
Schedule of Long-term Debt Maturities	Long-term debt matures as follows (in thousands): Fiscal Year Ending December 31, Minimum Payments 2019 $ — 2020 9,250 2021 9,250 2022 9,250 2023 9,250 2024 and beyond 1,288,000 Total $ 1,325,000
Schedule of Estimated Fair Values of Debt Obligations	The following table presents the estimated fair values of the Company’s debt obligations as of September 30, 2019 (in thousands): Financial Instrument Carrying Value as of September 30, 2019 Markets for Identical Item (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) First Lien Term Loan $ 892,729 $ — $ 922,688 $ — Second Lien Notes 373,669 — — 394,653 Total debt instruments $ 1,266,398 $ — $ 922,688 $ 394,653 The following table sets forth the changes in Level 3 measurements for the nine months ended September 30, 2019 (in thousands): Level 3 Measurements Previous Term Loans fair value as of January 1, 2019 $ 551,882 Change in fair value (369 ) Repayments of debt principal (2,075 ) Retirements of Previous Term Loans (549,438 ) Issuance of Second Lien Notes as of August 6, 2019 388,000 Change in fair value 6,653 Second Lien Notes fair value as of September 30, 2019 $ 394,653

DERIVATIVE INSTRUMENTS (Tables)

DERIVATIVE INSTRUMENTS (Tables)	9 Months Ended
	Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Amount and Location of Derivatives in the Balance Sheet	The following table summarizes the amount and location of the Company’s derivative instruments in the condensed consolidated balance sheets (in thousands): Fair value - Derivatives in asset position Derivative Balance Sheet Caption September 30, 2019 December 31, 2018 Interest rate caps designated as cash flow hedges Prepaids and other current assets $ — $ 2,627 Total derivatives $ — $ 2,627 Fair value - Derivatives in liability position Derivative Balance Sheet Caption September 30, 2019 December 31, 2018 Interest rate swaps designated as cash flow hedges Other non-current liabilities $ 7,883 $ — Interest rate swaps not designated as hedges Other non-current liabilities 120 — Total derivatives $ 8,003 $ —
Schedule of Pre-tax Income (Loss) Recognized in the Statements of Comprehensive Income (Loss)	The following table presents the pre-tax gains (losses) from derivative instruments recognized in other comprehensive (loss) income in the Company’s condensed consolidated statements of comprehensive income (loss) (in thousands): Three months ended September 30, Nine months ended September 30, Derivative 2019 2018 2019 2018 Interest rate caps designated as cash flow hedges $ (398 ) $ 221 $ (1,103 ) $ 2,165 Interest rate swaps designated as cash flow hedges (7,883 ) — (7,883 ) — $ (8,281 ) $ 221 $ (8,986 ) $ 2,165 The following table presents the amount and location of pre-tax income (loss) recognized in the Company’s condensed consolidated statement of comprehensive income (loss) related to the Company’s derivative instruments (in thousands): Three months ended September 30, Nine months ended September 30, Derivative Income Statement Caption 2019 2018 2019 2018 Interest rate caps designated as cash flow hedges Interest expense $ 269 $ 89 $ (125 ) $ 158 Interest rate swaps designated as cash flow hedges Interest expense 129 — 129 — Interest rate swaps not designated as hedges Interest expense (118 ) — (118 ) — $ 280 $ 89 $ (114 ) $ 158

NATURE OF OPERATIONS AND PRES_2

NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details) $ / shares in Units, $ in Thousands	Aug. 06, 2019USD ($)$ / sharesshares	Sep. 30, 2019USD ($)location$ / shares	Dec. 31, 2018USD ($)$ / shares
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) | $ / shares		$ 0.0001	$ 0.0001
Principal amount of debt | $		$ 1,266,398	$ 539,375
OptionCare Enterprises, Inc.
Business Acquisition [Line Items]
Shares converted in merger (in shares) | shares	542,261,567
Common stock, par value (in dollars per share) | $ / shares	$ 0.0001
Additional shares issued (in shares) | shares	28,193,428
Ownership retained by shareholders after merger	19.10%
Number of service locations | location		132
Preferred Stock and Certain Warrants | OptionCare Enterprises, Inc.
Business Acquisition [Line Items]
Shares repurchased | $	$ 125,800
Preferred Stock and Certain Warrants | Common Stock | OptionCare Enterprises, Inc.
Business Acquisition [Line Items]
Additional shares issued (in shares) | shares	3,458,412
HC Group Holdings I, LLC | OptionCare Enterprises, Inc.
Business Acquisition [Line Items]
Percentage of the combined company held	80.90%
Senior Notes | First Lien Term Loan
Business Acquisition [Line Items]
Principal amount of debt | $	$ 575,000

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Jan. 01, 2019
Concentration Risk [Line Items]
Operating lease liabilities	$ 83,964		$ 83,964		$ 83,964		$ 67,000
Operating lease right-of-use asset	$ 68,042	$ 0	$ 68,042		$ 68,042		$ 59,900
Revenue from Contract with Customer Benchmark | Company's Largest Payer
Concentration Risk [Line Items]
Concentration risk			15.00%	16.00%	13.00%	14.00%
Revenue from Contract with Customer Benchmark | Governmental Programs
Concentration Risk [Line Items]
Concentration risk			13.00%	11.00%	12.00%	11.00%
Accounts Receivable | Governmental Programs
Concentration Risk [Line Items]
Concentration risk	14.00%	13.00%
Cost of Goods and Service, Product and Service Benchmark | Medical Supply Vendors
Concentration Risk [Line Items]
Concentration risk			69.00%	75.00%	72.00%	76.00%
Overstatement Of Prior Period Goodwill
Concentration Risk [Line Items]
Amount of misstatement being corrected			$ (6,500)
Overstatement Of Prior Period Noncurrent Liabilities, Other
Concentration Risk [Line Items]
Amount of misstatement being corrected			$ 6,500

BUSINESS ACQUISITIONS - Additio

BUSINESS ACQUISITIONS - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	Aug. 06, 2019	Sep. 18, 2018	Aug. 08, 2018	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Goodwill				$ 1,419,373	$ 1,419,373	$ 631,884	$ 632,469	$ 632,469	$ 627,392	$ 627,392
Purchase price, net of cash acquired					700,170	$ 9,917
BioScrip
Business Acquisition [Line Items]
Share price (in dollars per share)	$ 2.67
Payment of shares in acquisition	$ 125,800
Success-based fees	14,100
Goodwill	786,904
Net sales since acquisition				119,100
Net loss since acquisition					19,400
Payments of transaction costs				$ 6,500	$ 19,300
Purchase price	1,102,001
Purchase price, net of cash acquired	1,087,214
Baptist Health In Little Rock, Arkansas
Business Acquisition [Line Items]
Purchase price			$ 1,000
Home I.V. Specialists, Inc.
Business Acquisition [Line Items]
Percentage of outstanding shares purchased		100.00%
Purchase price, net of cash acquired		$ 11,600
Senior Notes | First Lien Term Loan | BioScrip
Business Acquisition [Line Items]
Payment in settlement of debt	$ 575,000

BUSINESS ACQUISITIONS - Conside

BUSINESS ACQUISITIONS - Consideration Exchanged (Details) - USD ($) $ / shares in Units, $ in Thousands	Aug. 06, 2019	Sep. 30, 2019	Sep. 30, 2018	Aug. 05, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Number of BioScrip common shares outstanding at time of the merger (in shares)		705,207,530			570,454,995
Fair value of total consideration acquired, net of cash acquired		$ 700,170	$ 9,917
BioScrip
Business Acquisition [Line Items]
Number of BioScrip common shares outstanding at time of the merger (in shares)	132,639,000			129,181,000
Common shares issued to warrant and preferred stockholders at time of the merger (in shares)	3,458,000
BioScrip share price as of August 6, 2019 (in dollars per share)	$ 2.67
Fair value of common shares	$ 354,146
Fair value of share-based instruments	32,898
Cash paid in conjunction with the Merger included in purchase consideration	714,957
Fair value of total consideration transferred	1,102,001
Less: cash acquired	14,787
Fair value of total consideration acquired, net of cash acquired	$ 1,087,214

BUSINESS ACQUISITIONS - Acquire

BUSINESS ACQUISITIONS - Acquired Identifiable Assets and Assumed Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Aug. 06, 2019	Jun. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Goodwill	$ 1,419,373		$ 632,469	$ 632,469	$ 631,884	$ 627,392	$ 627,392
BioScrip
Business Acquisition [Line Items]
Accounts receivable, net		$ 97,163
Inventories		19,683
Property and equipment, net		49,697
Intangible assets, net		193,712
Deferred tax assets, net of deferred tax liabilities		26,731
Operating lease right-of-use asset		22,378
Operating lease liability		(28,897)
Accounts payable		(61,420)
Other assumed liabilities, net of other acquired assets		(18,737)
Total acquired identifiable assets and liabilities		300,310
Goodwill		786,904
Total consideration transferred		$ 1,087,214

BUSINESS ACQUISITIONS - Consi_2

BUSINESS ACQUISITIONS - Consideration Allocated to Intangible Assets (Details) - BioScrip $ in Thousands	Aug. 06, 2019USD ($)
Business Acquisition [Line Items]
Total intangible assets, net	$ 193,712
Weighted Average Estimated Life (in years)	18 years 10 months
Trademarks/Names
Business Acquisition [Line Items]
Total intangible assets, net	$ 12,681
Weighted Average Estimated Life (in years)	2 years
Patient referral sources
Business Acquisition [Line Items]
Total intangible assets, net	$ 180,652
Weighted Average Estimated Life (in years)	20 years
Licenses
Business Acquisition [Line Items]
Total intangible assets, net	$ 379
Weighted Average Estimated Life (in years)	1 year 6 months

BUSINESS ACQUISITIONS - Pro For

BUSINESS ACQUISITIONS - Pro Forma Financial Information (Details) - BioScrip - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Business Acquisition [Line Items]
Net revenue	$ 690,350	$ 674,890	$ 2,034,582	$ 1,959,395
Net loss	$ (18,686)	$ (7,919)	$ (54,181)	$ (59,670)

REVENUE - Impact of Adoption of

REVENUE - Impact of Adoption of Standards (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Condensed Consolidated Balance Sheets
Accounts receivable, net	$ 336,303		$ 336,303		$ 310,169
Condensed Consolidated Statement of Comprehensive Income (Loss)
Net revenue	615,880	$ 493,928	1,589,638	$ 1,434,061
Provision for doubtful accounts			0	0
Operating loss	(11,725)	$ 12,759	(14,600)	24,721
Condensed Consolidated Statements of Cash Flows
Accounts receivable, net			71,029	(32,483)
Prior to ASC 606 Adoption
Condensed Consolidated Balance Sheets
Accounts receivable, net	336,303		336,303		310,169
Condensed Consolidated Statement of Comprehensive Income (Loss)
Net revenue			1,644,903	1,479,058
Provision for doubtful accounts			(55,265)	(44,997)
Operating loss			(14,600)	24,721
Condensed Consolidated Statements of Cash Flows
Accounts receivable, net			71,029	(32,483)
Adjustments for ASC 606 | Adjustments for ASC 606
Condensed Consolidated Balance Sheets
Accounts receivable, net	$ 0		0		$ 0
Condensed Consolidated Statement of Comprehensive Income (Loss)
Net revenue			(55,265)	(44,997)
Provision for doubtful accounts			55,265	44,997
Operating loss			0	0
Condensed Consolidated Statements of Cash Flows
Accounts receivable, net			$ 0	$ 0

REVENUE - Net Revenue Earned by

REVENUE - Net Revenue Earned by Category of Payer (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Disaggregation of Revenue [Line Items]
Net revenue	$ 615,880	$ 493,928	$ 1,589,638	$ 1,434,061
Commercial payers
Disaggregation of Revenue [Line Items]
Net revenue	525,927	428,873	1,373,481	1,256,109
Government payers
Disaggregation of Revenue [Line Items]
Net revenue	80,280	56,511	194,875	160,939
Patients
Disaggregation of Revenue [Line Items]
Net revenue	$ 9,673	$ 8,544	$ 21,282	$ 17,013

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income tax (benefit) expense	$ 3,576	$ 383	$ (3,269)	$ (1,737)
Effective tax rate	(9.10%)	17.60%	5.20%	15.60%
State net operating losses	$ 1,000		$ 1,000

(LOSS) EARNINGS PER SHARE (Deta

(LOSS) EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Earnings Per Share [Abstract]
Dilutive potential common shares				$ 0				$ 0
Numerator:
Net (loss) income	$ (42,794,000)	$ (13,603,000)	$ (3,712,000)	$ 1,791,000	$ (4,309,000)	$ (6,851,000)	$ (60,109,000)	$ (9,369,000)
Denominator:
Weighted average number of common shares outstanding (in shares)	651,576			570,455			597,792	570,455
(Loss) Earnings per Common Share:
(Loss) earnings per common share, basic and diluted (in dollars per share)	$ (0.07)			$ 0			$ (0.10)	$ (0.02)

LEASES - Additional Information

LEASES - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Leases [Abstract]
Operating lease cost	$ 7.4		$ 21.5
Weighted-average remaining lease term, operating leases	5 years 3 months 19 days		5 years 3 months 19 days
Weighted-average discount rate, operating leases	5.41%		5.41%
Financing leases outstanding	$ 0.8		$ 0.8
Incurred rent expense		$ 4.5		$ 13

LEASES - Maturities of Lease Li

LEASES - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Jan. 01, 2019
Minimum Payments
Minimum Payments, Total lease payments, 2019	$ 6,793
Minimum Payments, Total lease payments, 2020	24,733
Minimum Payments, Total lease payments, 2021	19,026
Minimum Payments, Total lease payments, 2022	14,021
Minimum Payments, Total lease payments, 2023	10,614
Minimum Payments, Total lease payments, After 2024	24,582
Minimum Payments, Total lease payments	99,769
Less: Interest	15,805
Present value of lease liabilities	$ 83,964	$ 67,000

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 209,115		$ 209,115		$ 151,189
Less accumulated depreciation	77,133		77,133		58,047
Property and equipment, net	131,982		131,982		93,142
Depreciation expense	9,906	$ 5,427	21,704	$ 15,787
Infusion pumps
Property, Plant and Equipment [Line Items]
Property and equipment, gross	24,786		24,786		20,339
Equipment, furniture, and other
Property, Plant and Equipment [Line Items]
Property and equipment, gross	60,569		60,569		34,433
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	84,675		84,675		61,302
Computer software, purchased and internally developed
Property, Plant and Equipment [Line Items]
Property and equipment, gross	34,500		34,500		29,668
Assets under development
Property, Plant and Equipment [Line Items]
Property and equipment, gross	4,585		4,585		$ 5,447
Depreciation expense in cost of revenue
Property, Plant and Equipment [Line Items]
Depreciation expense	1,384	747	2,855	2,265
Depreciation expense in operating expenses
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 8,522	$ 4,680	$ 18,849	$ 13,522

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Goodwill [Roll Forward]
Goodwill - net book value, begging of period	$ 632,469	$ 627,392	$ 632,469	$ 627,392
Acquisitions	786,904	4,492	786,904	4,492
Goodwill - net book value, end of period	$ 1,419,373	$ 631,884	$ 1,419,373	$ 631,884

GOODWILL AND OTHER INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Total gross intangible assets	$ 483,526		$ 483,526		$ 293,943
Total accumulated amortization	(88,448)		(88,448)		(74,230)
Total intangible assets, net	395,078		395,078		219,713
Amortization expense for intangible assets	7,500	$ 4,900	$ 17,300	$ 14,700
Weighted average amortization period of intangibles			15 years 11 months
Referral sources
Finite-Lived Intangible Assets [Line Items]
Total gross intangible assets	438,445		$ 438,445		257,792
Total accumulated amortization	(77,749)		$ (77,749)		(63,353)
Weighted average amortization period of intangibles			17 years 1 month
Trademarks/names
Finite-Lived Intangible Assets [Line Items]
Total gross intangible assets	44,702		$ 44,702		32,000
Total accumulated amortization	(10,657)		$ (10,657)		(8,000)
Weighted average amortization period of intangibles			4 years 1 month
Other amortizable intangible assets
Finite-Lived Intangible Assets [Line Items]
Total gross intangible assets	379		$ 379		4,151
Total accumulated amortization	$ (42)		$ (42)		$ (2,877)
Weighted average amortization period of intangibles			1 year 6 months

EQUITY-METHOD INVESTMENTS - Add

EQUITY-METHOD INVESTMENTS - Additional Information (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2019USD ($)investment	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)investment	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2009USD ($)	Dec. 31, 2005USD ($)
Schedule of Equity Method Investments [Line Items]
Number of equity method investments | investment	2		2
Investments in equity-method investees	$ 16,100,000		$ 16,100,000		$ 14,600,000
Proportionate share of earnings in equity-method investees	800,000	$ 300,000	2,018,000	$ 656,000
Legacy Health Systems
Schedule of Equity Method Investments [Line Items]
Proportionate share of earnings in equity-method investees	$ 335,000	201,000	$ 588,000	612,000
Ownership interest	50.00%		50.00%
Initial investment							$ 1,300,000
Capital distribution received from investment	$ 500,000	0	$ 500,000	0
Vanderbilt Health Services
Schedule of Equity Method Investments [Line Items]
Proportionate share of earnings in equity-method investees	$ 491,000	$ 100,000	$ 1,430,000	$ 44,000
Ownership interest	50.00%		50.00%
Initial investment						$ 1,100,000

EQUITY-METHOD INVESTMENTS - Con

EQUITY-METHOD INVESTMENTS - Condensed Financial Information of Equity Method Investments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Consolidated statements of comprehensive income (loss) data:
Equity in net income	$ 800	$ 300	$ 2,018	$ 656
Legacy Health Systems
Consolidated statements of comprehensive income (loss) data:
Net revenue	5,814	5,572	15,210	15,728
Cost of revenue	4,083	3,853	10,882	11,132
Gross profit	1,731	1,719	4,328	4,596
Net income	670	402	1,177	1,225
Equity in net income	335	201	588	612
Consolidated balance sheet data:
Current assets	6,358		6,358		$ 5,666
Noncurrent assets	4,072		4,072		3,403
Current liabilities	572		572		119
Noncurrent liabilities	740		740		8
Vanderbilt Health Services
Consolidated statements of comprehensive income (loss) data:
Net revenue	9,638	7,659	28,701	22,055
Cost of revenue	7,473	5,718	21,989	16,943
Gross profit	2,165	1,941	6,712	5,112
Net income	982	199	2,859	88
Equity in net income	491	$ 100	1,430	$ 44
Consolidated balance sheet data:
Current assets	10,095		10,095		6,517
Noncurrent assets	2,206		2,206		1,008
Current liabilities	1,116		1,116		192
Noncurrent liabilities	$ 1,061		$ 1,061		$ 68

INDEBTEDNESS - Summary of Debt

INDEBTEDNESS - Summary of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Principal Amount	$ 1,325,000	$ 551,513
Discount	(20,557)	(1,062)
Debt Issuance Costs	(38,045)	(11,076)
Total	1,266,398	539,375
Less: current portion	(6,938)	(4,150)
Total long-term debt	1,259,460	535,225
Senior Notes | First Lien Term Loan
Debt Instrument [Line Items]
Principal Amount	925,000	401,513
Discount	(8,681)	(1,062)
Debt Issuance Costs	(23,590)	(5,678)
Total	892,729	394,773
Senior Notes | Second Lien Notes
Debt Instrument [Line Items]
Principal Amount	400,000	150,000
Discount	(11,876)	0
Debt Issuance Costs	(14,455)	(5,398)
Total	373,669	144,602
Senior Notes | Revolving Credit Facility
Debt Instrument [Line Items]
Principal Amount	0	0
Discount	0	0
Debt Issuance Costs	0	0
Total	$ 0	$ 0

INDEBTEDNESS - Additional Infor

INDEBTEDNESS - Additional Information (Details) - USD ($)	Aug. 06, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Aug. 31, 2019	Dec. 31, 2018	Dec. 31, 2015
Debt Instrument [Line Items]
Original issue discount		$ 20,557,000		$ 20,557,000			$ 1,062,000
Debt issuance costs		38,045,000		38,045,000			11,076,000
Principal amount of debt		1,266,398,000		1,266,398,000			539,375,000
Payments to extinguish debt				2,075,000	$ 4,112,000
Proceeds from issuance of debt				981,050,000	1,000,000
Loss on extinguishment of debt				5,469,000	72,000
Fees incurred netted against proceeds				36,538,000	$ 0
Senior Notes
Debt Instrument [Line Items]
Loss on extinguishment of debt	$ 5,500,000
Credit Arrangements Administered By Bank Of America, N.A. | Senior Notes
Debt Instrument [Line Items]
Face amount of debt instruments								$ 645,000,000
Loss on extinguishment of debt	(2,300,000)
Credit Agreements, Entered Into 2019 | Senior Notes
Debt Instrument [Line Items]
Face amount of debt instruments	1,475,000,000
Debt issuance costs	54,600,000
Proceeds from issuance of debt				981,100,000
Debt issuance costs and third party fees	59,100,000
Issuance costs expensed	1,300,000
Fees incurred netted against proceeds				21,300,000
Deferred financing costs				36,500,000
Deferred financing costs, investing activities				1,300,000
Credit Arrangements, Entered Into 2015, Modified Loans | Senior Notes
Debt Instrument [Line Items]
Debt issuance costs	7,600,000
Revolving Credit Facility | Senior Notes
Debt Instrument [Line Items]
Original issue discount		0		0			0
Debt issuance costs		0		0			0
Principal amount of debt		0		0			$ 0
Revolving Credit Facility | Credit Agreements, Entered Into 2019 | Senior Notes
Debt Instrument [Line Items]
Face amount of debt instruments	150,000,000
Principal amount of debt		$ 0		0
Commitment fee percentage		2.50%
Net borrowing availability		$ 140,400,000		140,400,000
Revolving Credit Facility | Minimum | Credit Agreements, Entered Into 2019 | Senior Notes
Debt Instrument [Line Items]
Commitment fee, unused portion		0.25%
Revolving Credit Facility | Minimum | Credit Agreements, Entered Into 2019 | Senior Notes | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate		1.25%
Revolving Credit Facility | Minimum | Credit Agreements, Entered Into 2019 | Senior Notes | Eurocurrency Rate
Debt Instrument [Line Items]
Basis spread on variable rate		2.25%
Revolving Credit Facility | Maximum | Credit Agreements, Entered Into 2019 | Senior Notes
Debt Instrument [Line Items]
Commitment fee, unused portion		0.375%
Revolving Credit Facility | Maximum | Credit Agreements, Entered Into 2019 | Senior Notes | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate		1.75%
Revolving Credit Facility | Maximum | Credit Agreements, Entered Into 2019 | Senior Notes | Eurocurrency Rate
Debt Instrument [Line Items]
Basis spread on variable rate		2.75%
Letters of Credit | Credit Agreements, Entered Into 2019 | Senior Notes
Debt Instrument [Line Items]
Undrawn letters of credit issued and outstanding		$ 9,600,000		$ 9,600,000
First Lien Term Loan | Senior Notes
Debt Instrument [Line Items]
Principal amount of debt	575,000,000
First Lien Term Loan | Credit Arrangements Administered By Bank Of America, N.A. | Senior Notes
Debt Instrument [Line Items]
Face amount of debt instruments								415,000,000
Original issue discount						$ 900,000		2,100,000
Debt issuance costs						4,700,000		21,100,000
Outstanding balance of debt repaid						393,800,000
Principal amount of debt						399,400,000
Effective rate on term loans at end of period							6.10%
Weighted average interest rate paid on term loans during period		6.06%	5.83%	6.20%	6.38%
First Lien Term Loan | Credit Agreements, Entered Into 2019 | Senior Notes
Debt Instrument [Line Items]
Face amount of debt instruments	925,000,000
Effective rate on term loans at end of period		6.61%		6.61%
Weighted average interest rate paid on term loans during period		6.67%
Quarterly installment payments		$ 2,300,000
Payments to extinguish debt	226,700,000
Proceeds from issuance of debt	752,400,000
First Lien Term Loan | Minimum | Credit Agreements, Entered Into 2019 | Senior Notes | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate		3.25%
First Lien Term Loan | Minimum | Credit Agreements, Entered Into 2019 | Senior Notes | Eurocurrency Rate
Debt Instrument [Line Items]
Basis spread on variable rate		4.25%
First Lien Term Loan | Maximum | Credit Agreements, Entered Into 2019 | Senior Notes | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate		3.50%
First Lien Term Loan | Maximum | Credit Agreements, Entered Into 2019 | Senior Notes | Eurocurrency Rate
Debt Instrument [Line Items]
Basis spread on variable rate		4.50%
Second Lien Term Loan | Credit Arrangements Administered By Bank Of America, N.A. | Senior Notes
Debt Instrument [Line Items]
Face amount of debt instruments								150,000,000
Debt issuance costs						4,200,000
Outstanding balance of debt repaid						145,800,000
Principal amount of debt						$ 150,000,000
Effective rate on term loans at end of period							11.15%
Weighted average interest rate paid on term loans during period		11.02%	11.09%	11.36%	10.68%
Second Lien Term Loan | Credit Agreements, Entered Into 2019 | Senior Notes
Debt Instrument [Line Items]
Face amount of debt instruments	400,000,000
Effective rate on term loans at end of period		10.89%		10.89%
Weighted average interest rate paid on term loans during period		10.89%
Payments to extinguish debt	0
Proceeds from issuance of debt	250,000,000
Loss on extinguishment of debt	$ 3,200,000
Second Lien Term Loan | Credit Agreements, Entered Into 2019 | Senior Notes | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate		1.00%
Second Lien Term Loan | Credit Agreements, Entered Into 2019 | Senior Notes | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate		8.75%
Bank Of America, N.A. | Revolving Credit Facility | Credit Arrangements Administered By Bank Of America, N.A. | Senior Notes
Debt Instrument [Line Items]
Face amount of debt instruments								$ 80,000,000

INDEBTEDNESS - Long-term Debt M

INDEBTEDNESS - Long-term Debt Maturities (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
2019	$ 0
2020	9,250
2021	9,250
2022	9,250
2023	9,250
2024 and beyond	1,288,000
Total	$ 1,325,000	$ 551,513

INDEBTEDNESS - Estimated Fair V

INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Repayments of debt principal	$ (2,075)	$ (4,112)
Issuance of Second Lien Notes as of August 6, 2019	981,050	$ 1,000
Senior Notes
Debt Instrument [Line Items]
Total debt instruments	1,266,398
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, end of period	1,266,398
Senior Notes | First Lien Term Loan
Debt Instrument [Line Items]
Total debt instruments	892,729
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, end of period	892,729
Senior Notes | Second Lien Notes
Debt Instrument [Line Items]
Total debt instruments	373,669
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, end of period	373,669
Senior Notes | Markets for Identical Item (Level 1)
Debt Instrument [Line Items]
Total debt instruments	0
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, end of period	0
Senior Notes | Markets for Identical Item (Level 1) | First Lien Term Loan
Debt Instrument [Line Items]
Total debt instruments	0
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, end of period	0
Senior Notes | Markets for Identical Item (Level 1) | Second Lien Notes
Debt Instrument [Line Items]
Total debt instruments	0
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, end of period	0
Senior Notes | Significant Other Observable Inputs (Level 2)
Debt Instrument [Line Items]
Total debt instruments	922,688
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, end of period	922,688
Senior Notes | Significant Other Observable Inputs (Level 2) | First Lien Term Loan
Debt Instrument [Line Items]
Total debt instruments	922,688
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, end of period	922,688
Senior Notes | Significant Other Observable Inputs (Level 2) | Second Lien Notes
Debt Instrument [Line Items]
Total debt instruments	0
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, end of period	0
Senior Notes | Significant Unobservable Inputs (Level 3)
Debt Instrument [Line Items]
Total debt instruments	551,882
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, beginning of period	551,882
Change in fair value	(369)
Repayments of debt principal	(2,075)
Retirements of Previous Term Loans	(549,438)
Total debt instruments, end of period	394,653
Senior Notes | Significant Unobservable Inputs (Level 3) | First Lien Term Loan
Debt Instrument [Line Items]
Total debt instruments	0
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, end of period	0
Senior Notes | Significant Unobservable Inputs (Level 3) | Second Lien Notes
Debt Instrument [Line Items]
Total debt instruments	394,653
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Change in fair value	6,653
Issuance of Second Lien Notes as of August 6, 2019	388,000
Total debt instruments, end of period	$ 394,653

DERIVATIVE INSTRUMENTS - Additi

DERIVATIVE INSTRUMENTS - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended
	Apr. 30, 2019	Nov. 06, 2019	Sep. 30, 2019	Aug. 31, 2019	Dec. 31, 2017
Derivative [Line Items]
Total interest rate costs expected to reclassify during next 12 months			$ 5.8
Interest Rate Swap
Derivative [Line Items]
Notional amount of derivative				$ 925
Designated as Hedging Instrument | Senior Notes | First Lien Term Loan | Credit Agreements, Entered Into 2019 | Interest Rate Cap
Derivative [Line Items]
Notional amount of derivative					$ 250
Not Designated as Hedging Instrument | Interest Rate Swap
Derivative [Line Items]
Notional amount of derivative				13.9
Cash Flow Hedging | Designated as Hedging Instrument | Interest Rate Cap
Derivative [Line Items]
Notional amount of derivative					$ 1.9
Proceeds from early termination of hedge	$ 1.7
Cash Flow Hedging | Designated as Hedging Instrument | Interest Rate Swap
Derivative [Line Items]
Notional amount of derivative				$ 911.1
Subsequent Event | Designated as Hedging Instrument | Senior Notes | Second Lien Term Loan | Credit Agreements, Entered Into 2019 | Interest Rate Swap
Derivative [Line Items]
Notional amount of derivative		$ 400

DERIVATIVE INSTRUMENTS - Balanc

DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Fair value - Derivatives in asset position
Total derivatives	$ 0	$ 2,627
Fair value - Derivatives in liability position
Total derivatives	8,003	0
Designated as Hedging Instrument | Prepaids and other current assets | Interest Rate Cap
Fair value - Derivatives in asset position
Interest rate caps designated as cash flow hedges	0	2,627
Designated as Hedging Instrument | Other non-current liabilities | Interest Rate Swap
Fair value - Derivatives in liability position
Interest rate swaps	7,883	0
Not Designated as Hedging Instrument | Other non-current liabilities | Interest Rate Swap
Fair value - Derivatives in liability position
Interest rate swaps	$ 120	$ 0

DERIVATIVE INSTRUMENTS - Pre-ta

DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Derivative [Line Items]
Pre-tax gains (losses) on interest rate derivatives recognized	$ (8,281)		$ (8,986)
Pre-tax gains (losses) on interest rate derivatives recognized		$ 221		$ 2,165
Total gain (loss) on derivatives	280	89	(114)	158
Interest Rate Cap
Derivative [Line Items]
Pre-tax gains (losses) on interest rate derivatives recognized	(398)		(1,103)
Pre-tax gains (losses) on interest rate derivatives recognized		221		2,165
Interest Rate Swap
Derivative [Line Items]
Pre-tax gains (losses) on interest rate derivatives recognized	(7,883)		(7,883)
Pre-tax gains (losses) on interest rate derivatives recognized		0		0
Interest expense | Interest Rate Cap
Derivative [Line Items]
Gain (loss) location of derivative instruments	269		(125)
Gain (loss) location of derivative instruments		89		158
Interest expense | Interest Rate Swap
Derivative [Line Items]
Gain (loss) location of derivative instruments	129		129
Gain (loss) location of derivative instruments		0		0
Gain (loss) location of derivative instruments not designated	$ (118)	$ 0	$ (118)	$ 0

FAIR VALUE MEASURMENTS (Details

FAIR VALUE MEASURMENTS (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Prepaids and other current assets | Interest Rate Cap | Designated as Hedging Instrument
Derivative [Line Items]
Interest rate caps designated as cash flow hedges	$ 0	$ 2,627

STOCK-BASED INCENTIVE COMPENS_2

STOCK-BASED INCENTIVE COMPENSATION (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	May 03, 2018
Stock Options
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation expense	$ 0.5
Restricted Stock
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation expense				$ 1.7
HC I Incentive Units
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation expense	$ 0.5	$ 0.6	$ 1.7	$ 1.7
The 2018 Plan
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of shares authorized (in shares)					16,406,939

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details) $ / shares in Units, $ in Millions	Aug. 06, 2019USD ($)shares	Sep. 30, 2019USD ($)shares	Sep. 30, 2019USD ($)shares	Dec. 31, 2016Days$ / sharesshares	Dec. 31, 2018shares	Jun. 29, 2017$ / sharesshares	Mar. 09, 2015$ / sharesshares
Class of Warrant or Right [Line Items]
Shares surrendered to satisfy tax withholding (in shares)		1,146,065	1,146,065
Value of shares surrendered to satisfy tax withholding obligations | $		$ 2.4	$ 2.4
Treasury stock held (in shares)		1,736,220	1,736,220		0
Preferred stock outstanding (in shares)		0	0		0
Common Stock | 2017 Warrants
Class of Warrant or Right [Line Items]
Number of shares purchasable through warrants (in shares)						8,300,000
Term of warrants						10 years
Exercise price of warrants (in dollars per share) | $ / shares						$ 2
Fair value of warrants | $	$ 14.1
Common Stock | 2015 Warrants
Class of Warrant or Right [Line Items]
Number of shares purchasable through warrants (in shares)							3,700,000
Term of warrants							10 years
Fair value of warrants | $	$ 4.6
Minimum | Common Stock | 2015 Warrants
Class of Warrant or Right [Line Items]
Exercise price of warrants (in dollars per share) | $ / shares							$ 5.17
Maximum | Common Stock | 2015 Warrants
Class of Warrant or Right [Line Items]
Exercise price of warrants (in dollars per share) | $ / shares							$ 6.45
OptionCare Enterprises, Inc.
Class of Warrant or Right [Line Items]
Common shares issued to warrant and preferred stockholders at time of the merger (in shares)	28,193,428
Restricted Stock Units (RSUs) | Home Solutions
Class of Warrant or Right [Line Items]
Shares issued pursuant to acquisition (in shares)				7,100,000
Tranche One | Restricted Stock Units (RSUs) | Home Solutions
Class of Warrant or Right [Line Items]
Shares issued pursuant to acquisition (in shares)				3,100,000
Stock price threshold (in dollars per share) | $ / shares				$ 4
Consecutive trading days threshold | Days				20
Tranche Two | Restricted Stock Units (RSUs) | Home Solutions
Class of Warrant or Right [Line Items]
Shares issued pursuant to acquisition (in shares)				4,000,000
Stock price threshold (in dollars per share) | $ / shares				$ 5
Consecutive trading days threshold | Days				20

RELATED-PARTY TRANSACTIONS (Det

RELATED-PARTY TRANSACTIONS (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Related Party Transaction [Line Items]
Sale of management notes receivable			$ 1,310,000	$ 0
Sale Of Notes Receivable
Related Party Transaction [Line Items]
Sale of management notes receivable	$ 1,300,000
HC Group Holdings I, LLC | Loans Funded For Membership Unit Purchase
Related Party Transaction [Line Items]
Amount credited to paid-in capital for membership units sold and funded			0	400,000
Shareholder redemptions	0	$ 0	2,400,000	0
Cash distributions			2,000,000
Notes redeemed			400,000
Management
Related Party Transaction [Line Items]
Notes receivable	0		0		$ 1,600,000
Management | Sale Of Notes Receivable
Related Party Transaction [Line Items]
Sale of management notes receivable	1,100,000
Accrued interest expense	200,000
Joint Venture
Related Party Transaction [Line Items]
Management fee income	600,000	$ 600,000	1,800,000	$ 1,600,000
Due to joint ventures	$ 3,100,000		$ 3,100,000		900,000
Due from joint ventures					$ 100,000